Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US2005/007410

International filing date: 07 March 2005 (07.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US

Number: 60/550,268


Filing date: 05 March 2004 (05.03.2004)

Date of receipt at the International Bureau: 27 July 2006 (27.07.2006)

Remark: Priority document submitted or transmitted to the International Bureau in

compliance with Rule 17.1(a) or (b)





'IO) ALLETO VITO INTERESE PRESENTS; SHAME (CONTES)

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

July 18, 2006

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/550,268

FILING DATE: March 05, 2004

RELATED PCT APPLICATION NUMBER: PCT/US05/07410

THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS CONVENTION, IS *US60/550,268*

1493637

Certified by

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office

PATENT ARCD:405USP1

PROVISIONAL APPLICATION FOR UNITED STATES LETTERS PATENT for

METHODS AND COMPOSITIONS RELATING TO THE PHARMACOGENETICS OF ABCC2 GENE VARIANTS

by

Mark J. Ratain

Federico Innocenti

Deanna L. Kroetz

and

Samir Undevia

CERTIFICATE OF EXPRESS MAIL

Express Mail No.: EV 414834592 US

Date of Deposit: March 5, 2004

BACKGROUND OF THE INVENTION

The government may own rights in the present invention pursuant to grant number GM61393 from the National Institutes of Health.

1. Field of the Invention

The present invention relates generally to the fields of molecular genetics, pharmacogenetics, and cancer therapy. In particular, the present invention is directed to methods and compositions for detecting polymorphisms and correlating the presence or absence of certain polymorphisms with toxic effects of chemotherapies. More specifically, the present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2 gene and correlating these polymorphisms with toxic effects of ABCC2 substrates, as well as evaluating the risk of an individual for developing toxicity to an ABCC2 substrate. In some embodiments, the invention concerns methods and compositions for predicting or anticipating the level of toxicity caused by an ABCC2 substrate, such as irinotecan, in a patient. Such methods and compositions can be used to evaluate whether irinotecan-based therapy, or therapy involving other ABCC2 substrates, may pose toxicity problems if given to a particular patient. Alterations in suggested therapy may ensue if a toxicity risk is assessed.

20

25

30

15

5

10

2. Description of Related Art

ATP-binding cassette (ABC) genes represent the largest family of transmembrane proteins that bind ATP and use the energy to drive the transport of various molecules across cell membranes. The products of the ABC genes are known to influence oral absorption and disposition of a wide variety of drugs and play a role in the resistance of malignant cells to anticancer agents (Sparreboom *et al.*, 2000).

ABCC2, a member of the ABC gene family, functions as the major exporter of organic anions from the liver into the bile. In addition, ABCC2 is expressed on the apical membrane of epithelial cells such as enterocytes, renal proximal tubule epithelia, and gall bladder epithelia. ABCC2 is also expressed in some tumor tissues such as ovarian carcinoma, colorectal carcinoma, leukemia, mesothelioma, and hepatocarcinoma; and it

has been suggested that tumor cells overexpressing ABCC2 acquire multidrug resistance (MDR) (Borst et al. (1999); Borst et al. (2000)).

ABCC2 substrates include intracellularly formed glucuronide and reduced glutathione (GSH)—conjugates of clinically important drugs (Suzuki *et al.*, 1998). In addition, ABCC2 is also involved in the biliary excretion of non-conjugated anionic drugs such as irinotecan (CPT-11).

Irinotecan is an antineoplastic drug used in the treatment of colon cancer. Irinotecan hydrolysis by carboxylesterase-2 (CES-2) is responsible for its activation to SN-38 (7-ethyl-10-hydroxycamptothecin), a topoisomerase I inhibitor of much higher potency than irinotecan. The main inactivating pathway of irinotecan is the biotransformation of active SN-38 into inactive SN-38 glucuronide (SN-38G) by UDP-glucuronosyltransferase 1A1 (UGT1A1) (Iyer *et al.*, 1998).

Despite its efficacy in treating metastatic colon cancer and its broad spectrum of activity in other tumor types, irinotecan treatment is associated with significant toxicity. The main severe toxicities of irinotecan are delayed diarrhea and myelosuppression. In the early single agent trials, grade 3-4 diarrhea occurred in about one third of patients and was dose limiting (Negoro et al., 1991; Rothenberg et al., 1993). Its frequency varies from study to study and is also schedule dependent. The frequency of grade 3-4 diarrhea in the three-weekly regimen (19%) is significantly lower compared to the weekly schedule (36%, Fuchs et al., 2003). In addition to diarrhea, grade 3-4 neutropenia is also a common adverse event, with about 30-40% of the patients experiencing it in both weekly and three-weekly regimens (Fuchs et al., 2003; Vanhoefer et al., 2001). Fatal events during irinotecan treatment have been reported. A high mortality rate of 5.3% and 1.6% was reported in the weekly and three-weekly single agent irinotecan regimens, respectively (Fuchs et al., 2003).

Interpatient differences in systemic formation of SN-38G have been shown to have clear clinical consequences in patients treated with irinotecan. Patients with higher glucuronidation of SN-38 are more likely to be protected from the dose limiting toxicity of diarrhea in the weekly schedule (Gupta *et al.*, 1994).

Improved methods and compositions for the evaluation of risk for irinotecan toxicity in an individual are still needed. Clearance of irinotecan and its metabolites by

5

10

15

20

25

ABCC2 represents a mechanism to protect patients from the toxic effects. However, the problem of identifying the effects of various polymorphisms on drug clearance by ABCC2 remains. Resolving these problems would provide novel methods and compositions for the evaluation of risk for toxicity to irinotecan as well as for numerous other drugs that are substrates for ABCC2.

SUMMARY OF THE INVENTION

The present invention is based on identification and characterization of correlations between genotype of the *ABCC2* gene and phenotype relating to the activity of ABCC2. Thus, the present invention provides methods and compositions that exploit correlations between genotype and phenotype concerning ABCC2. It is contemplated that such methods and compositions have diagnostic, prognostic, and therapeutic applications.

The present invention involves methods for determining the level of ABCC2 activity in a patient. This method can be used to predict what the level of ABCC2 activity is in a patient based on genotypic analysis. In some embodiments, the method involves determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 on one or both alleles is indicative of a normal level of ABCC2 activity.

Additional methods of the invention include a method for predicting tumor response to an anticancer agent that is an ABCC2 substrate in a cancer patient comprising determining the sequence at position 3972 in one or both alleles of the ABCC2 gene of the patient, wherein a C at position 3972 on one or both alleles is indicative of a greater chance of a reduced antitumor response to the anticancer agent. The probability of a reduced antitumor response is increased with respect to persons who do not have a C at position 3972. The determination of a T on both alleles at position 3972 in the ABCC2 gene is indicative of a greater chance of an antitumor response or of a better antitumor response than would be expected as compared to a person with a C at position 3972.

The term "antitumor response" means a response that results in a favorable therapeutic outcome with respect to a tumor. Examples of such an outcome include, but are not limited to, reduction in tumor size, retardation of tumor growth or proliferation, inhibition of metastasis, reduction in number of metastasis, inhibition of tumor

5

10

15

20

25

vasculature, inhibition of tumor growth rate, promotion of apoptosis of tumor cells, induction of tumor cell death or killing, promotion of remission of cancer growth, and extended survival. Thus, a reduced antitumor response means the patient may exhibit no response to the drug or that the response is less favorable than would be expected for someone with a TT genotype at position 3972. It will understood that the prediction of a reduced antitumor response may lead to an increased dosage (increased concentration, increased administration and/or both) and/or more aggressive treatment regimen than would have been the case for someone with the TT genotype. This altered treatment may overcome the predicted reduced antitumor response. Thus, embodiments of the invention further include adjusting dosage (concentration and/or administration (timing and/or frequency)) or route of administration of the anticancer agent or altering the treatment regimen overall. In some cases, the time between treatment regimens may be altered. In specific embodiments, the anticancer agent is irinotecan.

Other methods of the invention concern a method for determining dosage of an ABCC2 substrate for a patient comprising: a) determining the sequence at position 3972 in one or both alleles of the ABCC2 gene of the patient, wherein a C at position 3972 on one or both alleles indicates a higher dosage of the substrate than is indicated for a patient with a T at position 3972 in both alleles of the ABCC2 gene. In some embodiments, the ABCC2 substrate is selected from the group of substrates consisting of cysteinyl leukotrienes, glutathione and glutathione conjugates, glucuronide conjugates, sulfated conjugates, bile salt conjugates, bromosulfophthalein, and dibromosulfophthalein (see Table 1). Identified in Table 1 are substrates that are administered as drugs to patients. Determining the dosage of any of these drugs is specifically contemplated as part of the invention. In some cases, the dosage that would be given to a patient is modified based on the genotyping results based on methods of the invention. In certain embodiments, the substrate is irinotecan, SN-38, APC, and/or SN-38G. Methods of the invention also include prescribing a dosage of the anticancer agent, such as irinotecan, based on the determination of the sequence at position 3972 in one or both alleles of the ABCC2 gene. It is contemplated that a patient is given a different dosage than he or she would have otherwise received had the genotyping not been performed. Thus, in some embodiments

5

10

15

20

25

of the invention, a typical dosage is adjusted for a particular person (individualized therapy).

Methods of the invention also include monitoring for toxicity or adverse events once the ABBC2 substrate is administered, and possibly, adjusting or modifying dosage based on the those results. Toxicity indicators or indicators of adverse events include diarrhea, neutropenic fever, other hematologic toxicities, as well as known non-hematologic toxicities.

The present invention also concerns a method for predicting a clearance rate for irinotecan in a patient. The method involves determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 in one or both alleles is indicative of a normal clearance rate for irinotecan. Again, "normal" is with respect to the level of clearance that is expected for persons with the TT haplotype at position 3972. In additional embodiments, the clearance rate is determined empirically in that patient based on techniques that are well known to those of skill in the art. Identification of a T at position 3972 on both alleles of the *ABCC2* gene is indicative of a lower than normal clearance rate for irinotecan.

Reference to nucleotides (or residues) may be according to their well known abbreviations. A "C" refers to a cytosine; "T" refers to "thymine"; "A" refers to adenine; and, "G" refers to guanine. If mRNA is used to determine a nucleotide sequence, "U" refers to uracil. In one study, the allele frequency for the variant allele (T) at position 3972 was 38.3% in Caucasians (n=100) and 27.3% African Americans (n=100). It is understood that a C is the most common nucleotide at position 3972. Because of that and the observations discussed herein, the activity of ABCC2 will be characterized relative to the activity of ABCC2 in persons with a C at 3972. Consequently, a normalized level of activity of ABCC2 in persons with a C at 3972 will be understood as a "normal level of ABCC2 activity." Moreover, in some embodiments of the invention, identification of a T at position 3972 on both alleles of the *ABCC2* gene is indicative of a lower than normal level of ABCC2 activity.

It will be understood that the term "determine" is used according to its ordinary and plain meaning to indicate "to ascertain definitely by observation, examination,

5

10

15

20

25

calculation, etc.," according to the Oxford English Dictionary (2^{nd} ed.). It will also be understood that the phrase "determining the sequence at position X" means that the nucleotide at that position is directly or indirectly identified. In some embodiments, the sequence at a particular position is determined, while in other embodiments, what is determined at a particular position is that a particular nucleotide is *not* at that position.

Positions are indicated by conventional numbering where a negative sign (-) refers to nucleotides upstream (5') from the transcriptional start site (+1) (these sequences are in the promoter), unless otherwise designated. Sequences in the 5' untranslated region (5' UTR) may also be referred to using a negative sign, and in these cases, the positioning is with respect to the translated portion, where the first nucleotide of a codon is understood as +1. Positions downstream of the translational start site may or may not have a plus sign (+). Furthermore, unless otherwise indicated or understood, identification of a position downstream of the transcriptional start site refers to a position with respect to only the coding region of the gene, that is, its exons and not the introns. In some instances, positions within introns are referred to and the numbering for these positions is typically with respect to that intron alone, and not the gene as a whole.

It is contemplated that in methods of the invention, one or more sequences in one or both alleles of the *ABCC2* gene is determined. In some embodiments, both alleles of the patient are evaluated, while in others, only one allele is evaluated.

In further embodiments of the invention, methods also include obtaining a sample from a patient and using the sample to determine the sequence at position 3972. The sample may contain blood, serum, or a tissue biopsy, as well as buccal cells, mononuclear cells, or cancer cells.

Sequences may be determined by performing or conducting a hybridization assay, an amplification assay, particularly one that is allele-specific, a sequencing or microsequencing assay.

The sequence at position 3972 may be determined directly or indirectly. A direct determination involves performing an assay with respect to that position. An indirect determination means that the sequence at position 3972 is determined based on data regarding a different position, particularly by evaluating the sequence of a position in

5

10

15

20

25

linkage disequilibrium (LD) with a sequence at position 3972. In some embodiments, the sequence in LD with a sequence at position 3972 is in complete linkage disequilibrium with a sequence at 3972. In additional embodiments, the position in linkage disequilibrium with the sequence at position 3972 is selected from the group consisting of positions –1549 (promoter), -1019 (promoter), -24 (5' UTR), and +27 (intron 13). In some cases, more than one position in linkage disequilibrium with the sequence at position 3972 is evaluated to determine the sequence at position 3972. Therefore, in some embodiments of the invention, a haplotype that includes position 3972 is evaluated. In these embodiments, a determination of one or more sequences in one or both alleles of a gene in the haplotype is included in methods of the invention.

In methods of the invention, in some embodiments, an additional step of administering an ABCC2 substrate to the patient is included. Likewise, is some embodiments, the step of administering an anticancer agent to the patient is included in methods of the invention. In some cases, the amount, formulation, or timing of the administration is based on the genotypic analysis of position 3972 of the ABCC2 gene. In some embodiments of the invention, a patient is also provided additional anticancer therapy, such as the administration of a second anticancer agent or the performance of surgery on the patient. The second anticancer agent may be chemotherapy, particularly one that is not an ABCC2 substrate or not the same ABCC2 substrate that was already given to the patient, radiation therapy, immunotherapy, or gene therapy.

The present invention further concerns compositions that can be used to determine the sequence at position 3972 or any other sequence in LD with it. Accordingly, the present invention concerns kits for achieving methods of the invention. In some embodiments, the kits include one or more nucleic acids for determining the sequence at position 3972 in at one or both alleles of the *ABCC2* gene. In some embodiments, the nucleic acid is a primer for amplifying the sequence at position 3972 in the *ABCC2* gene. In others, the nucleic acid is a specific hybridization probe for detecting the sequence at position 3972 in the *ABCC2* gene. Additionally, it is contemplated that the specific hybridization probe can be comprised in an oligonucleotide array or microarray.

5

10

15

20

25

It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein. Similarly, any embodiment discussed with respect to one aspect of the invention may be used in the context of any other aspect of the invention.

Throughout this application, the term "about" is used to indicate that a value includes the standard deviation of error for the device or method being employed to determine the value.

The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and/or the specification may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one."

The use of the term "or" in the claims is used to mean "and/or" unless explicitly indicated to refer to alternatives only or the alternative are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and "and/or."

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

20

25

30

5

10

15

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIG. 1: ABCC2 3972C>T variant and AUC values of irinotecan and APC.

FIG. 2: ABCC2 3972C>T variant and AUC values of SN-38 and SN-38G.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The present invention provides improved methods and compositions for identifying the effects of polymorphisms in ABCC2 on the disposition of drugs and drug metabolites for the evaluation of the potential risk for drug toxicity or adverse events in an individual or patient. The development of these improved methods and compositions allows for the use of such an evaluation to optimize treatment of a patient and to lower the risk of toxicity or adverse events.

I. ABCC2

5

10

15

20

25

30

ABCC2, also referred to as MRP2 and cMOAT, functions as the major exporter of organic anions from the liver into the bile. In addition, ABCC2 is expressed on the apical membrane of epithelial cells such as enterocytes, renal proximal tubule epithelia, and gall bladder epithelia. ABCC2 is also expressed in some tumor tissues such as ovarian carcinoma, colorectal carcinoma, leukemia, mesothelioma, and hepatocarcinoma; and it has been suggested that tumor cells overexpressing ABCC2 acquire multidrug resistance (MDR) (Borst et al. (1999); Borst et al. (2000)).

ABCC2 is important from a pharmacological pint of view because it is involved in the clearance of several clinically important drugs. One such drug is the anticancer drug irinotecan (CPT-11).

Irinotecan is also inactivated to oxidated metabolites (including APC) by CYP3A enzymes, and is activated to SN-38, which has a 100-1,000-fold higher antitumor activity than irinotecan, by carboxylesterase-2 (CES-2). SN-38 is glucuronidated by hepatic uridine diphosphate glucuronosyltransferases (UGTs) to form SN-38 glucuronide (100-glucuronyl-SN-38, SN-38G), which is inactive and excreted into the bile and urine although, SN-38G might be deconjugated to form SN-38 by intestinal β-glucuronidase enzyme (Kaneda *et al.*, 1990). Irinotecan, SN-38, and SN-38G are known substrates for ABCC2. (Suzuki *et al.* (1999); Suzuki *et al.* (1998)).

The major dose-limiting toxicities of irinotecan include diarrhea and, to a lesser extent, myelosuppression. irinotecan-induced diarrhea can be serious and often does not respond adequately to conventional antidiarrheal agents (Takasuna *et al.*, 1995). This diarrhea may be due to direct enteric injury caused by the active metabolite, SN-38,

which has been shown to accumulate in the intestine after intra peritoneal administration of irinotecan in athymic mice (Araki *et al.*, 1993).

It has been shown that there is an inverse relationship between SN-38 glucuronidation rates and severity of diarrheal incidences in patients treated with increasing doses of Irinotecan (Gupta *et al.*, 1994). These findings indicate that glucuronidation of SN-38 protects against Irinotecan-induced gastrointestinal toxicity. Therefore, differential rates of SN-38 glucuronidation among subjects may explain the considerable inter-individual variation in the pharmacokinetic parameter estimates and toxicities observed after treatment with anti-cancer drugs or exposure to xenobiotics (Gupta *et al.*, 1994; Gupta *et al.*, 1997).

The present invention demonstrates that the synonymous 3972C>T (exon 28) in ABCC2 is correlated with AUC (area under the curve) for irinotecan (p=0.02), APC (p=<0.0001), APC/irinotecan ratio (p=<0.0001), SN-38G (p≤0.001), and SN-38G/SN-38 (p≤0.001). Furthermore, the TT 3972 genotype was associated with higher AUC of irinotecan (p=0.02), APC (p<0.0001), and SN-38G (p<0.0001) compared to CT and CC patients. The phenotypic effect of 3972C>T was previously unknown, and identifies 3972C>T as a variant potentially affecting ABCC2 activity and suggests its biological function and clinical relevance for ABCC2 substrates. Thus, the present invention provides improved methods and compositions for evaluating the disposition of drugs and drug metabolites, and for evaluating the potential risk for drug toxicity in an individual or patient. The development of these improved methods and compositions allows for the use of such an evaluation to optimize treatment of a patient and to lower the risk of toxicity.

AUC is a measure of how much drug reaches the bloodstream in a set period of time. AUC is calculated by plotting drug blood concentration at various times over a specified period of time, usually 24 hours, and then measuring the area under the curve. AUC has an number of important uses in toxicology, biopharmaceutics, and pharmacokinetics. It is understood to be the time course or exposure of the patient to the drug.

5

10

15

20

The metabolism of irinotecan is merely illustrative of the present invention; the metabolism of other ABCC2 substrates is also contemplated. A summary of ABCC2 substrates is provided in Table 1 below. The table includes ABCC2 drug substrates.

Table 1. ABCC2 Substrates

Cysteinyl Leukotrienes

LTC₄

5

LTD₄

LTE₄

N-acetylated LTE₄

GSH and GSH-Conjugates of Organic Compounds

Reduced glutathione (GSH)

Oxidized glutathione (GSSG)

2,4-dinitrophenol-S-glutathione

Glutathione-bimane

GSH Conjugate of bromosulfophthalein

GSH Conjugate of bromoisovalerylurea

GSH Conjugate of N-ethylmaleimide

GSH Conjugate of ethacrynic acid

GSH Conjugate of α-naphthylisothiocyanate

GSH Conjugate of methylfluoroscein

GSH Conjugate of prostaglandin A1

GSH Conjugate of (+)-anti-benzo[a]pyrene-7,8-diol-9,10-epoxide

GSH Conjugate of 4-hydroxynonenal

GSH Conjugates of Metals

Antimony

Arsenic

Bismuth

Cadmium

Copper

Silver

Zinc

Glucuronide Conjugates

Bilirubin monoglucuronide

Bilirubin diglucuronide

 17β estradiol 17β -D-glucuronide

Triiodothyronine-glucuronide

p-nitrophenol- β -D-glucuronide

1-naphytol-β-D-glucoronide

E3040 glucuronide

SN-38 glucuronide (SN-38G)

Grepafloxacin glucuronide

4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanol glucuronide

Telmisaltan glucuronide

Acetaminophen glucuronide

Diclofenac glucuronide

Indomethacin glucuronide

Glucuronide conjugates of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine

Liquiritigenin glucuronide

Glycyrrhizin

Sulfated Conjugates

Dehydroepiandrosterone sulfate

Bile Salt Conjugates

Cholate-3-O-glucuronide

Lithocholate-3-O-glucuronide

Chenodeoxycholate-3-O-glucuronide

Nordeoxycholate-3-O-glucuronide

Nordeoxycholate-3-sulfate

Lithocholate-3-sulfate

Taurolithocholate-3-sulfate

Glycolithocholate-3-sulfate

Taurochenodeoxycholate-3-sulfate

Non-Conjugated Compounds

Bromosulfophthalein

Dibromosulfophthalein

Carboxyfluorescein

Reduced folates

Methotrexate

CPT-11

SN-38

Ampicillin

Ceftriaxone

Cefodizime

Grepafloxacin

Pravastatin

Temocaprilat

BQ123

p-aminohippuric acid

Fluo-3

Sulfinpyrazone (GSH coupled)

Vinblastine (GSH coupled)

2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (GSH coupled)

Etroposide

Vincristine

Doxorubicin

Epirubicin

Cisplatin

II. NUCLEIC ACIDS

5

10

15

20

25

Certain embodiments of the present invention concern various nucleic acids, including amplification primers, oligonucleotide probes, and other nucleic acid elements involved in the analysis of genomic DNA. In certain aspects, a nucleic acid comprises a wild-type, a mutant, or a polymorphic nucleic acid.

The term "nucleic acid" is well known in the art. A "nucleic acid" as used herein will generally refer to a molecule (*i.e.*, a strand) of DNA, RNA or a derivative or analog thereof, comprising a nucleobase. A nucleobase includes, for example, a naturally occurring purine or pyrimidine base found in DNA (*e.g.*, an adenine "A," a guanine "G," a thymine "T" or a cytosine "C") or RNA (*e.g.*, an A, a G, an uracil "U" or a C). The term "nucleic acid" encompass the terms "oligonucleotide" and "polynucleotide," each as a subgenus of the term "nucleic acid." The term "oligonucleotide" refers to a molecule of between about 3 and about 100 nucleobases in length. The term "polynucleotide" refers to at least one molecule of greater than about 100 nucleobases in length. A "gene" refers to coding sequence of a gene product, as well as introns and the promoter of the gene product. In addition to the *ABCC2* gene, other regulatory regions such as enhancers for *ABCC2* are contemplated as nucleic acids for use with compositions and methods of the claimed invention.

In some embodiments, nucleic acids of the invention comprise or are complementary to all or 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240,

250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000 or more contiguous nucleotides of 1 (ABCC2 cDNA), SEQ ID NO:2 (ABCC2 exon 28), or SEQ ID NO:3.

These definitions generally refer to a single-stranded molecule, but in specific embodiments will also encompass an additional strand that is partially, substantially or fully complementary to the single-stranded molecule. Thus, a nucleic acid may encompass a double-stranded molecule or a triple-stranded molecule that comprises one or more complementary strand(s) or "complement(s)" of a particular sequence comprising a molecule. As used herein, a single stranded nucleic acid may be denoted by the prefix "ss", a double stranded nucleic acid by the prefix "ds", and a triple stranded nucleic acid by the prefix "ts."

In particular aspects, a nucleic acid encodes a protein, polypeptide, or peptide. In certain embodiments, the present invention concerns novel compositions comprising at least one proteinaceous molecule. As used herein, a "proteinaceous molecule," "proteinaceous composition," "proteinaceous compound," "proteinaceous chain," or "proteinaceous material" generally refers, but is not limited to, a protein of greater than about 200 amino acids or the full length endogenous sequence translated from a gene; a polypeptide of greater than about 100 amino acids; and/or a peptide of from about 3 to about 100 amino acids. All the "proteinaceous" terms described above may be used interchangeably herein.

1. Preparation of Nucleic Acids

A nucleic acid may be made by any technique known to one of ordinary skill in the art, such as for example, chemical synthesis, enzymatic production or biological production. Non-limiting examples of a synthetic nucleic acid (e.g., a synthetic oligonucleotide), include a nucleic acid made by *in vitro* chemical synthesis using phosphotriester, phosphite or phosphoramidite chemistry and solid phase techniques such as described in European Patent 266,032, incorporated herein by reference, or via deoxynucleoside H-phosphonate intermediates as described by Froehler et al., 1986 and

5

10

15

20

25

U.S. Patent 5,705,629, each incorporated herein by reference. In the methods of the present invention, one or more oligonucleotide may be used. Various different mechanisms of oligonucleotide synthesis have been disclosed in for example, U.S. Patents 4,659,774, 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146, 5,602,244, each of which is incorporated herein by reference.

A non-limiting example of an enzymatically produced nucleic acid include one produced by enzymes in amplification reactions such as PCRTM (see for example, U.S. Patent 4,683,202 and U.S. Patent 4,682,195, each incorporated herein by reference), or the synthesis of an oligonucleotide described in U.S. Patent 5,645,897, incorporated herein by reference. A non-limiting example of a biologically produced nucleic acid includes a recombinant nucleic acid produced (*i.e.*, replicated) in a living cell, such as a recombinant DNA vector replicated in bacteria (see for example, Sambrook *et al.* 2001, incorporated herein by reference).

2. Purification of Nucleic Acids

A nucleic acid may be purified on polyacrylamide gels, cesium chloride centrifugation gradients, chromatography columns or by any other means known to one of ordinary skill in the art (see for example, Sambrook *et al.*, 2001, incorporated herein by reference). In some aspects, a nucleic acid is a pharmacologically acceptable nucleic acid. Pharmacologically acceptable compositions are known to those of skill in the art, and are described herein.

In certain aspects, the present invention concerns a nucleic acid that is an isolated nucleic acid. As used herein, the term "isolated nucleic acid" refers to a nucleic acid molecule (e.g., an RNA or DNA molecule) that has been isolated free of, or is otherwise free of, the bulk of the total genomic and transcribed nucleic acids of one or more cells. In certain embodiments, "isolated nucleic acid" refers to a nucleic acid that has been isolated free of, or is otherwise free of, bulk of cellular components or in vitro reaction components such as for example, macromolecules such as lipids or proteins, small biological molecules, and the like.

3. Nucleic Acid Segments

In certain embodiments, the nucleic acid is a nucleic acid segment. As used herein, the term "nucleic acid segment," are fragments of a nucleic acid, such as, for a

5

10

15

20

25

non-limiting example, those that encode only part of a ABCC2 gene locus or a ABCC2 gene sequence. Thus, a "nucleic acid segment" may comprise any part of a gene sequence, including from about 2 nucleotides to the full length gene including promoter regions to the polyadenylation signal and any length that includes all the coding region.

Various nucleic acid segments may be designed based on a particular nucleic acid sequence, and may be of any length. By assigning numeric values to a sequence, for example, the first residue is 1, the second residue is 2, *etc.*, an algorithm defining all nucleic acid segments can be created:

n to n + y

where n is an integer from 1 to the last number of the sequence and y is the length of the nucleic acid segment minus one, where n + y does not exceed the last number of the sequence. Thus, for a 10-mer, the nucleic acid segments correspond to bases 1 to 10, 2 to 11, 3 to 12 ... and so on. For a 15-mer, the nucleic acid segments correspond to bases 1 to 15, 2 to 16, 3 to 17 ... and so on. For a 20-mer, the nucleic segments correspond to bases 1 to 20, 2 to 21, 3 to 22 ... and so on. In certain embodiments, the nucleic acid segment may be a probe or primer. As used herein, a "probe" generally refers to a nucleic acid used in a detection method or composition. As used herein, a "primer" generally refers to a nucleic acid used in an extension or amplification method or composition.

4. Nucleic Acid Complements

The present invention also encompasses a nucleic acid that is complementary to a nucleic acid. A nucleic acid is "complement(s)" or is "complementary" to another nucleic acid when it is capable of base-pairing with another nucleic acid according to the standard Watson-Crick, Hoogsteen or reverse Hoogsteen binding complementarity rules. As used herein "another nucleic acid" may refer to a separate molecule or a spatial separated sequence of the same molecule. In preferred embodiments, a complement is a hybridization probe or amplification primer for the detection of a nucleic acid polymorphism.

As used herein, the term "complementary" or "complement" also refers to a nucleic acid comprising a sequence of consecutive nucleobases or semiconsecutive nucleobases (e.g., one or more nucleobase moieties are not present in the molecule) capable of hybridizing to another nucleic acid strand or duplex even if less than all the

5

10

15

20

25

nucleobases do not base pair with a counterpart nucleobase. However, in some diagnostic or detection embodiments, completely complementary nucleic acids are preferred.

5 III. NUCLEIC ACID DETECTION

10

15

20

25

30

Some embodiments of the invention concern identifying polymorphisms in ABCC2, correlating genotype or haplotype to phenotype, wherein the phenotype is altered ABCC2 activity or expression, and then identifying such polymorphisms in patients who have or will be given irinotecan or other drugs or compounds that are ABCC2 substrates. Thus, the present invention involves assays for identifying polymorphisms and other nucleic acid detection methods. Nucleic acids, therefore, have utility as probes or primers for embodiments involving nucleic acid hybridization. They may be used in diagnostic or screening methods of the present invention. Detection of nucleic acids encoding ABCC2, as well as nucleic acids involved in the expression or stability of ABCC2 polypeptides or transcripts, are encompassed by the invention. General methods of nucleic acid detection methods are provided below, followed by specific examples employed for the identification of polymorphisms, including single nucleotide polymorphisms (SNPs).

A. Hybridization

The use of a probe or primer of between 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50, 60, 70, 80, 90, or 100 nucleotides, preferably between 17 and 100 nucleotides in length, or in some aspects of the invention up to 1-2 kilobases or more in length, allows the formation of a duplex molecule that is both stable and selective. Molecules having complementary sequences over contiguous stretches greater than 20 bases in length are generally preferred, to increase stability and/or selectivity of the hybrid molecules obtained. One will generally prefer to design nucleic acid molecules for hybridization having one or more complementary sequences of 20 to 30 nucleotides, or even longer where desired. Such fragments may be readily prepared, for example, by directly synthesizing the fragment by chemical means or by introducing selected sequences into recombinant vectors for recombinant production.

Accordingly, the nucleotide sequences of the invention may be used for their ability to selectively form duplex molecules with complementary stretches of DNAs and/or RNAs or to provide primers for amplification of DNA or RNA from samples. Depending on the application envisioned, one would desire to employ varying conditions of hybridization to achieve varying degrees of selectivity of the probe or primers for the target sequence.

For applications requiring high selectivity, one will typically desire to employ relatively high stringency conditions to form the hybrids. For example, relatively low salt and/or high temperature conditions, such as provided by about 0.02 M to about 0.10 M NaCl at temperatures of about 50°C to about 70°C. Such high stringency conditions tolerate little, if any, mismatch between the probe or primers and the template or target strand and would be particularly suitable for isolating specific genes or for detecting a specific polymorphism. It is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide. For example, under highly stringent conditions, hybridization to filter-bound DNA may be carried out in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1 x SSC/0.1% SDS at 68°C (Ausubel *et al.*, 1989).

Conditions may be rendered less stringent by increasing salt concentration and/or decreasing temperature. For example, a medium stringency condition could be provided by about 0.1 to 0.25M NaCl at temperatures of about 37°C to about 55°C, while a low stringency condition could be provided by about 0.15M to about 0.9M salt, at temperatures ranging from about 20°C to about 55°C. Under low stringent conditions, such as moderately stringent conditions the washing may be carried out for example in 0.2 x SSC/0.1% SDS at 42°C (Ausubel *et al.*, 1989). Hybridization conditions can be readily manipulated depending on the desired results.

In other embodiments, hybridization may be achieved under conditions of, for example, 50mM Tris-HCl (pH 8.3), 75mM KCl, 3mM MgCl₂, 1.0mM dithiothreitol, at temperatures between approximately 20°C to about 37°C. Other hybridization conditions utilized could include approximately 10mM Tris-HCl (pH 8.3), 50mM KCl, 1.5mM MgCl₂, at temperatures ranging from approximately 40°C to about 72°C.

5

10

15

20

25

In certain embodiments, it will be advantageous to employ nucleic acids of defined sequences of the present invention in combination with an appropriate means, such as a label, for determining hybridization. A wide variety of appropriate indicator means are known in the art, including fluorescent, radioactive, enzymatic or other ligands, such as avidin/biotin, which are capable of being detected. In preferred embodiments, one may desire to employ a fluorescent label or an enzyme tag such as urease, alkaline phosphatase or peroxidase, instead of radioactive or other environmentally undesirable reagents. In the case of enzyme tags, colorimetric indicator substrates are known that can be employed to provide a detection means that is visibly or spectrophotometrically detectable, to identify specific hybridization with complementary nucleic acid containing samples. In other aspects, a particular nuclease cleavage site may be present and detection of a particular nucleotide sequence can be determined by the presence or absence of nucleic acid cleavage.

In general, it is envisioned that the probes or primers described herein will be useful as reagents in solution hybridization, as in PCR, for detection of expression or genotype of corresponding genes, as well as in embodiments employing a solid phase. In embodiments involving a solid phase, the test DNA (or RNA) is adsorbed or otherwise affixed to a selected matrix or surface. This fixed, single-stranded nucleic acid is then subjected to hybridization with selected probes under desired conditions. The conditions selected will depend on the particular circumstances (depending, for example, on the G+C content, type of target nucleic acid, source of nucleic acid, size of hybridization probe, etc.). Optimization of hybridization conditions for the particular application of interest is well known to those of skill in the art. After washing of the hybridized molecules to remove non-specifically bound probe molecules, hybridization is detected, and/or quantified, by determining the amount of bound label. Representative solid phase hybridization methods are disclosed in U.S. Patents 5,843,663, 5,900,481 and 5,919,626. Other methods of hybridization that may be used in the practice of the present invention are disclosed in U.S. Patents 5,849,481, 5,849,486 and 5,851,772. The relevant portions of these and other references identified in this section of the Specification are incorporated herein by reference.

5

10

15

20

25

B. Amplification of Nucleic Acids

Nucleic acids used as a template for amplification may be isolated from cells, tissues or other samples according to standard methodologies (Sambrook *et al.*, 2001). In certain embodiments, analysis is performed on whole cell or tissue homogenates or biological fluid samples with or without substantial purification of the template nucleic acid. The nucleic acid may be genomic DNA or fractionated or whole cell RNA. Where RNA is used, it may be desired to first convert the RNA to a complementary DNA.

The term "primer," as used herein, is meant to encompass any nucleic acid that is capable of priming the synthesis of a nascent nucleic acid in a template-dependent process. Typically, primers are oligonucleotides from ten to twenty and/or thirty base pairs in length, but longer sequences can be employed. Primers may be provided in double-stranded and/or single-stranded form, although the single-stranded form is preferred.

Pairs of primers designed to selectively hybridize to nucleic acids corresponding to the ABCC2 gene locus (GenBank accession NT030059, incorporated herein by reference), or variants thereof, and fragments thereof are contacted with the template nucleic acid under conditions that permit selective hybridization. Depending upon the desired application, high stringency hybridization conditions may be selected that will only allow hybridization to sequences that are completely complementary to the primers. In other embodiments, hybridization may occur under reduced stringency to allow for amplification of nucleic acids that contain one or more mismatches with the primer sequences. Once hybridized, the template-primer complex is contacted with one or more enzymes that facilitate template-dependent nucleic acid synthesis. Multiple rounds of amplification, also referred to as "cycles," are conducted until a sufficient amount of amplification product is produced.

The amplification product may be detected, analyzed or quantified. In certain applications, the detection may be performed by visual means. In certain applications, the detection may involve indirect identification of the product via chemiluminescence, radioactive scintigraphy of incorporated radiolabel or fluorescent label or even via a system using electrical and/or thermal impulse signals (Affymax technology; Bellus, 1994).

5

10

15

20

25

A number of template dependent processes are available to amplify the oligonucleotide sequences present in a given template sample. One of the best known amplification methods is the polymerase chain reaction (referred to as PCRTM) which is described in detail in U.S. Patents 4,683,195, 4,683,202 and 4,800,159, and in Innis *et al.*, 1988, each of which is incorporated herein by reference in their entirety.

Another method for amplification is ligase chain reaction ("LCR"), disclosed in European Application No. 320 308, incorporated herein by reference in its entirety. U.S. Patent 4,883,750 describes a method similar to LCR for binding probe pairs to a target sequence. A method based on PCR™ and oligonucleotide ligase assay (OLA) (described in further detail below), disclosed in U.S. Patent 5,912,148, may also be used.

Alternative methods for amplification of target nucleic acid sequences that may be used in the practice of the present invention are disclosed in U.S. Patents 5,843,650, 5,846,709, 5,846,783, 5,849,546, 5,849,497, 5,849,547, 5,858,652, 5,866,366, 5,916,776, 5,922,574, 5,928,905, 5,928,906, 5,932,451, 5,935,825, 5,939,291 and 5,942,391, Great Britain Application 2 202 328, and in PCT Application PCT/US89/01025, each of which is incorporated herein by reference in its entirety. Qbeta Replicase, described in PCT Application PCT/US87/00880, may also be used as an amplification method in the present invention.

An isothermal amplification method, in which restriction endonucleases and ligases are used to achieve the amplification of target molecules that contain nucleotide 5'-[alpha-thio]-triphosphates in one strand of a restriction site may also be useful in the amplification of nucleic acids in the present invention (Walker *et al.*, 1992). Strand Displacement Amplification (SDA), disclosed in U.S. Patent 5,916,779, is another method of carrying out isothermal amplification of nucleic acids which involves multiple rounds of strand displacement and synthesis, *i.e.*, nick translation

Other nucleic acid amplification procedures include transcription-based amplification systems (TAS), including nucleic acid sequence based amplification (NASBA) and 3SR (Kwoh et al., 1989; PCT Application WO 88/10315, incorporated herein by reference in their entirety). European Application 329 822 disclose a nucleic acid amplification process involving cyclically synthesizing single-stranded RNA

5

10

15

20

25

("ssRNA"), ssDNA, and double-stranded DNA (dsDNA), which may be used in accordance with the present invention.

PCT Application WO 89/06700 (incorporated herein by reference in its entirety) disclose a nucleic acid sequence amplification scheme based on the hybridization of a promoter region/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence. This scheme is not cyclic, *i.e.*, new templates are not produced from the resultant RNA transcripts. Other amplification methods include "RACE" and "one-sided PCR" (Frohman, 1990; Ohara *et al.*, 1989).

C. Detection of Nucleic Acids

Following any amplification, it may be desirable to separate the amplification product from the template and/or the excess primer. In one embodiment, amplification products are separated by agarose, agarose-acrylamide or polyacrylamide gel electrophoresis using standard methods (Sambrook *et al.*, 2001). Separated amplification products may be cut out and eluted from the gel for further manipulation. Using low melting point agarose gels, the separated band may be removed by heating the gel, followed by extraction of the nucleic acid.

Separation of nucleic acids may also be effected by spin columns and/or chromatographic techniques known in art. There are many kinds of chromatography which may be used in the practice of the present invention, including adsorption, partition, ion-exchange, hydroxylapatite, molecular sieve, reverse-phase, column, paper, thin-layer, and gas chromatography as well as HPLC.

In certain embodiments, the amplification products are visualized, with or without separation. A typical visualization method involves staining of a gel with ethidium bromide and visualization of bands under UV light. Alternatively, if the amplification products are integrally labeled with radio- or fluorometrically-labeled nucleotides, the separated amplification products can be exposed to x-ray film or visualized under the appropriate excitatory spectra.

In one embodiment, following separation of amplification products, a labeled nucleic acid probe is brought into contact with the amplified marker sequence. The probe preferably is conjugated to a chromophore but may be radiolabeled. In another

5

10

15

20

25

embodiment, the probe is conjugated to a binding partner, such as an antibody or biotin, or another binding partner carrying a detectable moiety.

In particular embodiments, detection is by Southern blotting and hybridization with a labeled probe. The techniques involved in Southern blotting are well known to those of skill in the art (see Sambrook *et al.*, 2001). One example of the foregoing is described in U.S. Patent 5,279,721, incorporated by reference herein, which discloses an apparatus and method for the automated electrophoresis and transfer of nucleic acids. The apparatus permits electrophoresis and blotting without external manipulation of the gel and is ideally suited to carrying out methods according to the present invention.

Other methods of nucleic acid detection that may be used in the practice of the instant invention are disclosed in U.S. Patents 5,840,873, 5,843,640, 5,843,651, 5,846,708, 5,846,717, 5,846,726, 5,846,729, 5,849,487, 5,853,990, 5,853,992, 5,853,993, 5,856,092, 5,861,244, 5,863,732, 5,863,753, 5,866,331, 5,905,024, 5,910,407, 5,912,124, 5,912,145, 5,919,630, 5,925,517, 5,928,862, 5,928,869, 5,929,227, 5,932,413 and 5,935,791, each of which is incorporated herein by reference.

D. Other Assays

5

10

15

20

25

30

Other methods for genetic screening may be used within the scope of the present invention, for example, to detect mutations in genomic DNA, cDNA and/or RNA samples. Methods used to detect point mutations include denaturing gradient gel electrophoresis ("DGGE"), restriction fragment length polymorphism analysis ("RFLP"), chemical or enzymatic cleavage methods, direct sequencing of target regions amplified by PCRTM (see above), single-strand conformation polymorphism analysis ("SSCP") and other methods well known in the art.

One method of screening for point mutations is based on RNase cleavage of base pair mismatches in RNA/DNA or RNA/RNA heteroduplexes. As used herein, the term "mismatch" is defined as a region of one or more unpaired or mispaired nucleotides in a double-stranded RNA/RNA, RNA/DNA or DNA/DNA molecule. This definition thus includes mismatches due to insertion/deletion mutations, as well as single or multiple base point mutations.

U.S. Patent 4,946,773 describes an RNase A mismatch cleavage assay that involves annealing single-stranded DNA or RNA test samples to an RNA probe, and

subsequent treatment of the nucleic acid duplexes with RNase A. For the detection of mismatches, the single-stranded products of the RNase A treatment, electrophoretically separated according to size, are compared to similarly treated control duplexes. Samples containing smaller fragments (cleavage products) not seen in the control duplex are scored as positive.

Other investigators have described the use of RNase I in mismatch assays. The use of RNase I for mismatch detection is described in literature from Promega Biotech. Promega markets a kit containing RNase I that is reported to cleave three out of four known mismatches. Others have described using the MutS protein or other DNA-repair enzymes for detection of single-base mismatches.

Alternative methods for detection of deletion, insertion or substitution mutations that may be used in the practice of the present invention are disclosed in U.S. Patents 5,849,483, 5,851,770, 5,866,337, 5,925,525 and 5,928,870, each of which is incorporated herein by reference in its entirety.

E. Specific Examples of SNP Screening Methods

Spontaneous mutations that arise during the course of evolution in the genomes of organisms are often not immediately transmitted throughout all of the members of the species, thereby creating polymorphic alleles that co-exist in the species populations. Often polymorphisms are the cause of genetic diseases. Several classes of polymorphisms have been identified. For example, variable nucleotide type polymorphisms (VNTRs), arise from spontaneous tandem duplications of di- or trinucleotide repeated motifs of nucleotides. If such variations alter the lengths of DNA fragments generated by restriction endonuclease cleavage, the variations are referred to as restriction fragment length polymorphisms (RFLPs). RFLPs are been widely used in human and animal genetic analyses.

Another class of polymorphisms are generated by the replacement of a single nucleotide. Such single nucleotide polymorphisms (SNPs) rarely result in changes in a restriction endonuclease site. Thus, SNPs are rarely detectable restriction fragment length analysis. SNPs are the most common genetic variations and occur once every 100 to 300 bases and several SNP mutations have been found that affect a single nucleotide in a protein-encoding gene in a manner sufficient to actually cause a genetic disease. SNP

5

10

15

20

25

diseases are exemplified by hemophilia, sickle-cell anemia, hereditary hemochromatosis, late-onset alzheimer disease *etc*.

In context of the present invention, polymorphic mutations that affect the activity and/or level of the *ABCC2* gene product, which is responsible for the transport of numerous compounds across cell membranes, will be determined by a series of screening methods. To do this, a sample (such as blood or other bodily fluid or tissue sample) will be taken from a patient for genotype analysis. The presence or absence of SNPs will determine the ability of the screened individuals to metabolize irinotecan and other agents that are transported by ABCC2. According to methods provided by the invention, these results will be used to adjust and/or alter the dose of irinotecan or other agent administered to an individual in order to reduce drug side effects. In one embodiment, the presence of the 3972C>T variant in the *ABCC2* gene will be determined. The identification of a T at position 3972 on both alleles would indicate that the patient will be slower to dispose of ABCC2 substrates (e.g., irinotecan) than a patient with a C at position 3972 on one or both alleles. Thus, to minimize drug toxicity, it may be desirable to administer a lower drug dose to the patient having a T at position 3972 on both alleles.

In some embodiments, the methods and compositions of the present invention involve determining the sequence at polymorphic sites in linkage disequilibrium with the sequence at position 3972 of the *ABCC2* gene. For example, a common haplotype with the 3972 variant is one that includes two promoter variants (-1549A>G and -1019A>G) and a 5' UTR variant (-24C>T). Another haplotype including the 3972 variant and the -1549 and -1019 promoter variants is also common. Thus, in certain embodiments, the methods and compositions of the present invention comprise detecting one or more of the -1549A>G, -1019A>G, or -24C>T variants in the *ABCC2* gene. Yet another haplotype with the 3972 variant includes the -1549A>G promoter variant and an intronic variant in intron 13 (+27C>G). Thus, in certain embodiments, the methods and compositions of the present invention comprise detecting one or both of the -1549A>G or +27C>G variants in the *ABCC2* gene.

SNPs can be the result of deletions, point mutations and insertions and in general any single base alteration, whatever the cause, can result in a SNP. The greater frequency of SNPs means that they can be more readily identified than the other classes of

5

10

15

20

25

polymorphisms. The greater uniformity of their distribution permits the identification of SNPs "nearer" to a particular trait of interest. The combined effect of these two attributes makes SNPs extremely valuable. For example, if a particular trait (e.g., inability to efficiently metabolize irinotecan) reflects a mutation at a particular locus, then any polymorphism that is linked to the particular locus can be used to predict the probability that an individual will be exhibit that trait.

Several methods have been developed to screen polymorphisms and some examples are listed below. The reference of Kwok and Chen (2003) and Kwok (2001) provide overviews of some of these methods; both of these references are specifically incorporated by reference.

SNPs relating to ABCC2 can be characterized by the use of any of these methods or suitable modification thereof. Such methods include the direct or indirect sequencing of the site, the use of restriction enzymes where the respective alleles of the site create or destroy a restriction site, the use of allele-specific hybridization probes, the use of antibodies that are specific for the proteins encoded by the different alleles of the polymorphism, or any other biochemical interpretation.

i) DNA Sequencing

The most commonly used method of characterizing a polymorphism is direct DNA sequencing of the genetic locus that flanks and includes the polymorphism. Such analysis can be accomplished using either the "dideoxy-mediated chain termination method," also known as the "Sanger Method" (Sanger et al., 1975) or the "chemical degradation method," also known as the "Maxam-Gilbert method" (Maxam et al., 1977). Sequencing in combination with genomic sequence-specific amplification technologies, such as the polymerase chain reaction may be utilized to facilitate the recovery of the desired genes (Mullis et al., 1986; European Patent Application 50,424; European Patent Application. 84,796, European Patent Application 258,017, European Patent Application. 237,362; European Patent Application. 201,184; U.S. Patents 4,683,202; 4,582,788; and 4,683,194), all of the above incorporated herein by reference.

ii) Exonuclease Resistance

Other methods that can be employed to determine the identity of a nucleotide present at a polymorphic site utilize a specialized exonuclease-resistant nucleotide

5

10

15

20

25

derivative (U.S. Patent. 4,656,127). A primer complementary to an allelic sequence immediately 3'-to the polymorphic site is hybridized to the DNA under investigation. If the polymorphic site on the DNA contains a nucleotide that is complementary to the particular exonucleotide-resistant nucleotide derivative present, then that derivative will be incorporated by a polymerase onto the end of the hybridized primer. Such incorporation makes the primer resistant to exonuclease cleavage and thereby permits its detection. As the identity of the exonucleotide-resistant derivative is known one can determine the specific nucleotide present in the polymorphic site of the DNA.

iii) Microsequencing Methods

Several other primer-guided nucleotide incorporation procedures for assaying polymorphic sites in DNA have been described (Komher *et al.*, 1989; Sokolov, 1990; Syvanen 1990; Kuppuswamy *et al.*, 1991; Prezant *et al.*, 1992; Ugozzoll *et al.*, 1992; Nyren *et al.*, 1993). These methods rely on the incorporation of labeled deoxynucleotides to discriminate between bases at a polymorphic site. As the signal is proportional to the number of deoxynucleotides incorporated, polymorphisms that occur in runs of the same nucleotide result in a signal that is proportional to the length of the run (Syvanen *et al.*,1990).

iv) Extension in Solution

French Patent 2,650,840 and PCT Application WO91/02087 discuss a solution-based method for determining the identity of the nucleotide of a polymorphic site. According to these methods, a primer complementary to allelic sequences immediately 3'-to a polymorphic site is used. The identity of the nucleotide of that site is determined using labeled dideoxynucleotide derivatives which are incorporated at the end of the primer if complementary to the nucleotide of the polymorphic site.

v) Genetic Bit Analysis or Solid-Phase Extension

PCT Application WO92/15712 describes a method that uses mixtures of labeled terminators and a primer that is complementary to the sequence 3' to a polymorphic site. The labeled terminator that is incorporated is complementary to the nucleotide present in the polymorphic site of the target molecule being evaluated and is thus identified. Here the primer or the target molecule is immobilized to a solid phase.

5

10

15

20

25

vi) Oligonucleotide Ligation Assay (OLA)

This is another solid phase method that uses different methodology (Landegren et al., 1988). Two oligonucleotides, capable of hybridizing to abutting sequences of a single strand of a target DNA are used. One of these oligonucleotides is biotinylated while the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate. Ligation permits the recovery of the labeled oligonucleotide by using avidin. Other nucleic acid detection assays, based on this method, combined with PCR have also been described (Nickerson et al., 1990). Here PCR is used to achieve the exponential amplification of target DNA, which is then detected using the OLA.

vii) Ligase/Polymerase-Mediated Genetic Bit Analysis

U.S. Patent 5,952,174 describes a method that also involves two primers capable of hybridizing to abutting sequences of a target molecule. The hybridized product is formed on a solid support to which the target is immobilized. Here the hybridization occurs such that the primers are separated from one another by a space of a single nucleotide. Incubating this hybridized product in the presence of a polymerase, a ligase, and a nucleoside triphosphate mixture containing at least one deoxynucleoside triphosphate allows the ligation of any pair of abutting hybridized oligonucleotides. Addition of a ligase results in two events required to generate a signal, extension and ligation. This provides a higher specificity and lower "noise" than methods using either extension or ligation alone and unlike the polymerase-based assays, this method enhances the specificity of the polymerase step by combining it with a second hybridization and a ligation step for a signal to be attached to the solid phase.

viii) Other Methods To Detect SNPs

Several other specific methods for SNP detection and identification are presented below and may be used as such or with suitable modifications in conjunction with identifying polymorphisms of the *ABCC2* gene in the present invention. Several other methods are also described on the SNP web site of the NCBI at the website www.ncbi.nlm.nih.gov/SNP, incorporated herein by reference.

5

10

15

20

25

In a particular embodiment, extended haplotypes may be determined at any given locus in a population, which allows one to identify exactly which SNPs will be redundant and which will be essential in association studies. The latter is referred to as 'haplotype tag SNPs (htSNPs)', markers that capture the haplotypes of a gene or a region of linkage disequilibrium. See Johnson *et al.* (2001) and Ke and Cardon (2003), each of which is incorporated herein by reference, for exemplary methods.

The VDA-assay utilizes PCR amplification of genomic segments by long PCR methods using TaKaRa LA Taq reagents and other standard reaction conditions. The long amplification can amplify DNA sizes of about 2,000-12,000 bp. Hybridization of products to variant detector array (VDA) can be performed by a Affymetrix High Throughput Screening Center and analyzed with computerized software.

A method called Chip Assay uses PCR amplification of genomic segments by standard or long PCR protocols. Hybridization products are analyzed by VDA, Halushka *et al.* (1999), incorporated herein by reference. SNPs are generally classified as "Certain" or "Likely" based on computer analysis of hybridization patterns. By comparison to alternative detection methods such as nucleotide sequencing, "Certain" SNPs have been confirmed 100% of the time; and "Likely" SNPs have been confirmed 73% of the time by this method.

Other methods simply involve PCR amplification following digestion with the relevant restriction enzyme. Yet others involve sequencing of purified PCR products from known genomic regions.

In yet another method, individual exons or overlapping fragments of large exons are PCR-amplified. Primers are designed from published or database sequences and PCR-amplification of genomic DNA is performed using the following conditions: 200 ng DNA template, 0.5µM each primer, 80µM each of dCTP, dATP, dTTP and dGTP, 5% formamide, 1.5mM MgCl₂, 0.5U of Taq polymerase and 0.1 volume of the Taq buffer. Thermal cycling is performed and resulting PCR-products are analyzed by PCR-single strand conformation polymorphism (PCR-SSCP) analysis, under a variety of conditions, e.g, 5 or 10% polyacrylamide gel with 15% urea, with or without 5% glycerol. Electrophoresis is performed overnight. PCR-products that show mobility shifts are reamplified and sequenced to identify nucleotide variation.

5

10

15

20

25

In a method called CGAP-GAI (DEMIGLACE), sequence and alignment data (from a PHRAP.ace file), quality scores for the sequence base calls (from PHRED quality files), distance information (from PHYLIP dnadist and neighbour programs) and basecalling data (from PHRED '-d' switch) are loaded into memory. Sequences are aligned and examined for each vertical chunk ('slice') of the resulting assembly for disagreement. Any such slice is considered a candidate SNP (DEMIGLACE). A number of filters are used by DEMIGLACE to eliminate slices that are not likely to represent true polymorphisms. These include filters that: (i) exclude sequences in any given slice from SNP consideration where neighboring sequence quality scores drop 40% or more; (ii) exclude calls in which peak amplitude is below the fifteenth percentile of all base calls for that nucleotide type; (iii) disqualify regions of a sequence having a high number of disagreements with the consensus from participating in SNP calculations; (iv) removed from consideration any base call with an alternative call in which the peak takes up 25% or more of the area of the called peak; (v) exclude variations that occur in only one read direction. PHRED quality scores were converted into probability-of-error values for each nucleotide in the slice. Standard Baysian methods are used to calculate the posterior probability that there is evidence of nucleotide heterogeneity at a given location.

In a method called CU-RDF (RESEQ), PCR amplification is performed from DNA isolated from blood using specific primers for each SNP, and after typical cleanup protocols to remove unused primers and free nucleotides, direct sequencing using the same or nested primers.

In a method called DEBNICK (METHOD-B), a comparative analysis of clustered EST sequences is performed and confirmed by fluorescent-based DNA sequencing. In a related method, called DEBNICK (METHOD-C), comparative analysis of clustered EST sequences with phred quality > 20 at the site of the mismatch, average phred quality >= 20 over 5 bases 5'-FLANK and 3' to the SNP, no mismatches in 5 bases 5' and 3' to the SNP, at least two occurrences of each allele is performed and confirmed by examining traces.

In a method identified by ERO (RESEQ), new primers sets are designed for electronically published STSs and used to amplify DNA from 10 different mouse strains. The amplification product from each strain is then gel purified and sequenced using a

5

10

15

20

25

standard dideoxy, cycle sequencing technique with ³³P-labeled terminators. All the ddATP terminated reactions are then loaded in adjacent lanes of a sequencing gel followed by all of the ddGTP reactions and so on. SNPs are identified by visually scanning the radiographs.

In another method identified as ERO (RESEQ-HT), new primers sets are designed for electronically published murine DNA sequences and used to amplify DNA from 10 different mouse strains. The amplification product from each strain is prepared for sequencing by treating with Exonuclease I and Shrimp Alkaline Phosphatase. Sequencing is performed using ABI Prism Big Dye Terminator Ready Reaction Kit (Perkin-Elmer) and sequence samples are run on the 3700 DNA Analyzer (96 Capillary Sequencer).

FGU-CBT (SCA2-SNP) identifies a method where the region containing the SNP were PCR amplified using the primers SCA2-FP3 and SCA2-RP3. Approximately 100 ng of genomic DNA is amplified in a 50 ml reaction volume containing a final concentration of 5mM Tris, 25mM KCl, 0.75mM MgCl₂, 0.05% gelatin, 20pmol of each primer and 0.5U of Taq DNA polymerase. Samples are denatured, annealed and extended and the PCR product is purified from a band cut out of the agarose gel using, for example, the QIAquick gel extraction kit (Qiagen) and is sequenced using dye terminator chemistry on an ABI Prism 377 automated DNA sequencer with the PCR primers.

In a method identified as JBLACK (SEQ/RESTRICT), two independent PCR reactions are performed with genomic DNA. Products from the first reaction are analyzed by sequencing, indicating a unique FspI restriction site. The mutation is confirmed in the product of the second PCR reaction by digesting with Fsp I.

In a method described as KWOK(1), SNPs are identified by comparing high quality genomic sequence data from four randomly chosen individuals by direct DNA sequencing of PCR products with dye-terminator chemistry (see Kwok et al., 1996). In a related method identified as KWOK(2) SNPs are identified by comparing high quality genomic sequence data from overlapping large-insert clones such as bacterial artificial chromosomes (BACs) or P1-based artificial chromosomes (PACs). An STS containing this SNP is then developed and the existence of the SNP in various populations is

5

10

15

20

25

confirmed by pooled DNA sequencing (see Taillon-Miller *et al.*, 1998). In another similar method called KWOK(3), SNPs are identified by comparing high quality genomic sequence data from overlapping large-insert clones BACs or PACs. The SNPs found by this approach represent DNA sequence variations between the two donor chromosomes but the allele frequencies in the general population have not yet been determined. In method KWOK(5), SNPs are identified by comparing high quality genomic sequence data from a homozygous DNA sample and one or more pooled DNA samples by direct DNA sequencing of PCR products with dye-terminator chemistry. The STSs used are developed from sequence data found in publicly available databases. Specifically, these STSs are amplified by PCR against a complete hydatidiform mole (CHM) that has been shown to be homozygous at all loci and a pool of DNA samples from 80 CEPH parents (see Kwok *et al.*, 1994).

In another such method, KWOK (OverlapSnpDetectionWithPolyBayes), SNPs are discovered by automated computer analysis of overlapping regions of large-insert human genomic clone sequences. For data acquisition, clone sequences are obtained directly from large-scale sequencing centers. This is necessary because base quality sequences are not present/available through GenBank. Raw data processing involves analyzed of clone sequences and accompanying base quality information for consistency. Finished ('base perfect', error rate lower than 1 in 10,000 bp) sequences with no associated base quality sequences are assigned a uniform base quality value of 40 (1 in 10,000 bp error rate). Draft sequences without base quality values are rejected. Processed sequences are entered into a local database. A version of each sequence with known human repeats masked is also stored. Repeat masking is performed with the program "MASKERAID." Overlap detection: Putative overlaps are detected with the program "WUBLAST." Several filtering steps followed in order to eliminate false overlap detection results, i.e. similarities between a pair of clone sequences that arise due to sequence duplication as opposed to true overlap. Total length of overlap, overall percent similarity, number of sequence differences between nucleotides with high base quality value "high-quality mismatches." Results are also compared to results of restriction fragment mapping of genomic clones at Washington University Genome Sequencing Center, finisher's reports on overlaps, and results of the sequence contig

5

10

15

20

25

building effort at the NCBI. SNP detection: Overlapping pairs of clone sequence are analyzed for candidate SNP sites with the 'POLYBAYES' SNP detection software. Sequence differences between the pair of sequences are scored for the probability of representing true sequence variation as opposed to sequencing error. This process requires the presence of base quality values for both sequences. High-scoring candidates are extracted. The search is restricted to substitution-type single base pair variations. Confidence score of candidate SNP is computed by the POLYBAYES software.

In method identified by KWOK (TaqMan assay), the TaqMan assay is used to determine genotypes for 90 random individuals. In method identified by KYUGEN(Q1), DNA samples of indicated populations are pooled and analyzed by PLACE-SSCP. Peak heights of each allele in the pooled analysis are corrected by those in a heterozygote, and are subsequently used for calculation of allele frequencies. Allele frequencies higher than 10% are reliably quantified by this method. Allele frequency = 0 (zero) means that the allele was found among individuals, but the corresponding peak is not seen in the examination of pool. Allele frequency = 0-0.1 indicates that minor alleles are detected in the pool but the peaks are too low to reliably quantify.

In yet another method identified as KYUGEN (Method1), PCR products are post-labeled with fluorescent dyes and analyzed by an automated capillary electrophoresis system under SSCP conditions (PLACE-SSCP). Four or more individual DNAs are analyzed with or without two pooled DNA (Japanese pool and CEPH parents pool) in a series of experiments. Alleles are identified by visual inspection. Individual DNAs with different genotypes are sequenced and SNPs identified. Allele frequencies are estimated from peak heights in the pooled samples after correction of signal bias using peak heights in heterozygotes. For the PCR primers are tagged to have 5'-ATT or 5'-GTT at their ends for post-labeling of both strands. Samples of DNA (10 ng/ul) are amplified in reaction mixtures containing the buffer (10mM Tris-HCl, pH 8.3 or 9.3, 50mM KCl, 2.0mM MgCl₂), 0.25μM of each primer, 200μM of each dNTP, and 0.025 units/μl of Taq DNA polymerase premixed with anti-Taq antibody. The two strands of PCR products are differentially labeled with nucleotides modified with R110 and R6G by an exchange reaction of Klenow fragment of DNA polymerase I. The reaction is stopped by adding EDTA, and unincorporated nucleotides are dephosphorylated by adding calf intestinal

5

10

15

20

25

alkaline phosphatase. For the SSCP: an aliquot of fluorescently labeled PCR products and TAMRA-labeled internal markers are added to deionized formamide, and denatured. Electrophoresis is performed in a capillary using an ABI Prism 310 Genetic Analyzer. Genescan softwares (P-E Biosystems) are used for data collection and data processing. DNA of individuals (two to eleven) including those who showed different genotypes on SSCP are subjected for direct sequencing using big-dye terminator chemistry, on ABI Prism 310 sequencers. Multiple sequence trace files obtained from ABI Prism 310 are processed and aligned by Phred/Phrap and viewed using Consed viewer. SNPs are identified by PolyPhred software and visual inspection.

In yet another method identified as KYUGEN (Method2), individuals with different genotypes are searched by denaturing HPLC (DHPLC) or PLACE-SSCP (Inazuka et al., 1997) and their sequences are determined to identify SNPs. PCR is performed with primers tagged with 5'-ATT or 5'-GTT at their ends for post-labeling of both strands. DHPLC analysis is carried out using the WAVE DNA fragment analysis system (Transgenomic). PCR products are injected into DNASep column, and separated under the conditions determined using WAVEMaker program (Transgenomic). The two strands of PCR products that are differentially labeled with nucleotides modified with R110 and R6G by an exchange reaction of Klenow fragment of DNA polymerase I. The reaction is stopped by adding EDTA, and unincorporated nucleotides are dephosphorylated by adding calf intestinal alkaline phosphatase. SSCP followed by electrophoresis is performed in a capillary using an ABI Prism 310 Genetic Analyzer. Genescan softwares (P-E Biosystems). DNA of individuals including those who showed different genotypes on DHPLC or SSCP are subjected for direct sequencing using bigdye terminator chemistry, on ABI Prism 310 sequencer. Multiple sequence trace files obtained from ABI Prism 310 are processed and aligned by Phred/Phrap and viewed using Consed viewer. SNPs are identified by PolyPhred software and visual inspection. Trace chromatogram data of EST sequences in Unigene are processed with PHRED. To identify likely SNPs, single base mismatches are reported from multiple sequence alignments produced by the programs PHRAP, BRO and POA for each Unigene cluster. BRO corrected possible misreported EST orientations, while POA identified and analyzed non-linear alignment structures indicative of gene mixing/chimeras that might

5

10

15

20

25

produce spurious SNPs. Bayesian inference is used to weigh evidence for true polymorphism versus sequencing error, misalignment or ambiguity, misclustering or chimeric EST sequences, assessing data such as raw chromatogram height, sharpness, overlap and spacing; sequencing error rates; context-sensitivity; cDNA library origin, etc.

In method identified as MARSHFIELD(Method-B), overlapping human DNA sequences which contained putative insertion/deletion polymorphisms are identified through searches of public databases. PCR primers which flanked each polymorphic site are selected from the consensus sequences. Primers are used to amplify individual or pooled human genomic DNA. Resulting PCR products are resolved on a denaturing polyacrylamide gel and a PhosphorImager is used to estimate allele frequencies from DNA pools.

6. Linkage Disequilibrium

Polymorphisms in linkage disequilibrium with the polymorphism at 3972 of the ABCC2 gene locus may also be used with the methods of the present invention. "Linkage disequilibrium" ("LD" as used herein, though also referred to as "LED" in the art) refers to a situation where a particular combination of alleles (i.e., a variant form of a given gene) or polymorphisms at two loci appears more frequently than would be expected by chance. "Significant" as used in respect to linkage disequilibrium, as determined by one of skill in the art, is contemplated to be a statistical p or α value that may be 0.25 or 0.1 and may be 0.1, 0.05. 0.001, 0.00001 or less. The relationship between ABCC2 haplotypes and the AUC of ABCC2 substrates may be used to correlate the genotype (i.e., the genetic make up of an organism) to a phenotype (i.e., the physical traits displayed by an organism or cell). "Haplotype" is used according to its plain and ordinary meaning to one skilled in the art. It refers to a collective genotype of two or more alleles or polymorphisms along one of the homologous chromosomes.

A common haplotype with the 3972 variant includes two promoter variants (-1549A>G and -1019A>G) and a 5'UTR variant (-24C>T). This is found at a frequency of 17.3% in Caucasian, 4.3% in African-Americans, and 10.3% in Asian populations. The 3972 variant is found alone at a frequency of 5.2% in Caucasians and 4.6% in

5

10

15

20

25

African-Americans. A haplotype including the 3972 variant and the -1549 and -1019 promoter variants has a frequency of 9.2% in Caucasians, and 3.7% in African-Americans. Another haplotype with the 3972 variant includes the -1549A>G promoter variant and an intronic variant in intron 13 (+27C>G). This haplotype is found at a frequency of 4.8% in African-Americans.

V. FORMULATIONS AND DOSAGES

5

10

15

20

25

Irinotecan is also known as CPT-11 and it is commercially available as CAMPTOSAR®. CAMPTOSAR® is supplied as a sterile solution in two single-dose sizes: 2-mL vials containing 40 mg irinoteccan hydrochloride and 5-mL vials containing 100 mg irinotecan hydrochloride. Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, which is an alkaloid extract from plants including *Camptotheca acuminata*.

CAMPTOSAR® Injection can be administered as a monotherapy, but in some instances is indicated as one agent of a first-line therapy to treat colon or rectal cancer. It has been used in combination with 5-fluorouracil (5-FU) and leucovorin. In some cases, this combination treatment is indicated for patient with recurrent or progressed cancer, after they have undergone a fluorouracil-based therapy.

It can be adminstered by intravenous infusion. Dosages of CAMPTOSAR® include 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 400 or more mg/m² on day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 26, 37 or on a weekly regimen, such as every 1, 2, 3, 4 weeks or more for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more consecutive or non-consecutive weeks. It is contemplated that dosages can be adjusted to be less than or more than the concentrations discussed above or less frequently or more frequently than the timing discussed above. It is contemplated treatment cycles may be repeated and that there may be a respite between cycles. One of ordinary skill in the art

is familiar with dosages regimens. In one example of a typical regimen for single-agent CAMPTOSAR® treatment, a patient is provided 125 mg/m2 IV over 90 minutes on day 1, 8, 15, 22, then a two week rest before the cycle may be resumed. The overall amount of the drug administered to the patient in a single regimen or for the treatment overall may be increased or decreased by about, by at least about, or by at most about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000 mg/m² or any ranges derivable therein.

The dosages of other ABCC2 drug substrates (drugs are included in Table 1) that are administered to patients is well known to those of skill in the art. These dosages may be reduced or increased relative to a dosage that would have been administered in the absence of genotyping. It is specifically contemplated that the dosages of any of those drugs may be similarly altered or modified based on genotypic analysis described herein.

15 V. KITS

5

10

20

25

30

Any of the compositions described herein may be comprised in a kit. In a non-limiting example, reagents for determining the genotype of one or both *ABCC2* genes are included in a kit. The kit may further include individual nucleic acids that can be used to amplify and/or detect particular nucleic acid sequences of the *ABCC2* gene. It may also include one or more buffers, such as a DNA isolation buffers, an amplification buffer or a hybridization buffer. The kit may also contain compounds and reagents to prepare DNA templates and isolate DNA from a sample. The kit may also include various labeling reagents and compounds.

The components of the kits may be packaged either in aqueous media or in lyophilized form. The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which a component may be placed, and preferably, suitably aliquoted. Where there is more than one component in the kit, the kit also will generally contain a second, third or other additional container into which the additional components may be separately placed. However, various combinations of components may be comprised in a vial. The kits of the present

invention also will typically include a means for containing the nucleic acids, and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow-molded plastic containers into which the desired vials are retained.

When the components of the kit are provided in one and/or more liquid solutions, the liquid solution is an aqueous solution, with a sterile aqueous solution being particularly preferred. However, the components of the kit may be provided as dried powder(s). When reagents and/or components are provided as a dry powder, the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container means.

A kit will also include instructions for employing the kit components as well the use of any other reagent not included in the kit. Instructions may include variations that can be implemented.

It is contemplated that such reagents are embodiments of kits of the invention. Such kits, however, are not limited to the particular items identified above and may include any reagent used directly or indirectly in the detection of polymorphisms in the *ABCC2* gene, particularly the 3972C>T polymorphism. Kits include, in some embodiments, nucleic acids capable of amplifying or of probing for a polymorphism in the *ABCC2* gene.

20

5

10

15

EXAMPLES

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

30

EXAMPLE 1

CORRELATION OF THE 3972C>T VARIANT OF *ABCC2* WITH IRINOTECAN PHARMACOKINETICS

Sixty-four adults (48 Caucasians, 10 African-Americans, 4 Hispanics, and 2 others) with refractory solid tumors took part in the pharmacogenetic study. Genotyping of common variants (q > 0.10 in individuals of African and Caucasian origin) was performed for the following genes (number of variants in parenthesis): CES-2 (n=2), ABCC1 (n=7), ABCC2 (n=6), ABCB1 (n=8), CYP3A4*1B (n=1), CYP3A5*3 (n=1), UGT1A9 (n=1), and HNF-1α (n=1) (Table 2).

Gene	Location	Position
CES-2	16q22.1	-363C>G, 5'UTR
CES-2	16q22.1	1361G>A, intron 1
ABCC1	16p13.1	1062T>C, synonymous
ABCC1	16p13.1	8A>G, intron 9
ABCC1	16p13.1	-48C>, intron 11
ABCC1	16p13.1	1684T>C, synonymous
ABCC1	16p13.1	-30C>G, intron 18
ABCC1	16p13.1	4002G>A, synonymous
ABCC1	16p13.1	18A>G, intron 30
ABCC2	10q24	-1549A>G, promoter
ABCC2	10q24	-1019A>G, promoter
ABCC2	10q24	-24C>T, 5'UTR
ABCC2	10q24	1249G>A, nonsynonymous, Val417Ile
ABCC2	10q24	-34T>C, intron 26
ABCC2	10q24	3972C>T, synonymous
ABCB1	7q21.1	-129T>C, 5'UTR
ABCB1	7q21.1	-25G>T, intron 4
ABCB1	7q21.1	-44A>G, intron 9
ABCB1	7q21.1	1236C>T, synonymous
ABCB1	7q21.1	24C>T, intron 13
ABCB1	7q21.1	+38A>G, intron 14
ABCB1	7q21.1	2677G>T/A, nonsynonymous, Ala893Ser/Thr
ABCB1	7q21.1	3435C>T, synonymous
CYP3A4*1B	7q21.1	-392A>G, promoter
CYP3A5*3	7q21.1	22893G>A
UGT1A9	2q37	-11810T/9T, exon 1, AF297093
HNF1α	12q24.2	79A>C, nonsynonymous I27L, exon 1, NM_000545.3

Table 2. Genetic variants typed in this study.

Irinotecan, SN-38, SN-38G, and APC AUCs were measured using noncompartmental analysis (WinNonlin) in the 64 patients in the study after a 350 mg/m² IV dose of irinotecan. AUC ratios of SN-38/ irinotecan, APC/ irinotecan, and SN-38G/SN-38 were also calculated. After visual inspection of the graphical plots of AUC and ratios stratified by genotype, t test analysis was applied to the data showing the possible presence of an inter-genotype difference in irinotecan pharmacokinetics.

The synonymous 3972C>T (exon 28) in ABCC2 was correlated with irinotecan AUC (p=0.02) (FIG. 1), APC AUC (p=<0.0001) (FIG. 1), and SN-38G AUC (p≤0.001) (FIG. 2), with the TT patients showing higher AUC values compared to CT and CC patients. Higher values of AUC ratios in the TT patients compared to CT and CC patients were also observed in relation to APC/irinotecan (p=<0.0001) and SN-38G/SN-38 (p≤0.001). For SN-38 and SN-38G AUCs, the correlation with 3972C>T was analyzed in patients with 6/6 and 6/7 UGT1A1 genotype (n=54) to avoid confounding effects of 7/7 genotypes. No significant correlation was observed between SN-38 AUC and 3972C>T (p=0.9) (FIG. 2). The frequency of CC, CT, and TT genotypes in the sample population was 0.44, 0.44, and 0.13, respectively. Other gene variants showed either no or borderline statistical significance in the anova test.

20 * * * *

All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents that are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and

5

10

15

25

modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

- U.S. Patent 4,582,788
- U.S. Patent 4,659,774
- U.S. Patent 4,683,194
- 10 U.S. Patent 4,683,195
 - U.S. Patent 4,683,202
 - U.S. Patent 4,683,202
 - U.S. Patent 4,683,202
 - U.S. Patent 4,800,159
- 15 U.S. Patent 4,816,571
 - U.S. Patent 4,883,750
 - U.S. Patent 4,946,773
 - U.S. Patent 4,959,463
 - U.S. Patent 5,141,813
- 20 U.S. Patent 5,264,566
 - U.S. Patent 5,279,721
 - U.S. Patent 5,428,148
 - U.S. Patent 5,554,744
 - U.S. Patent 5,574,146
- 25 U.S. Patent 5,602,244
 - U.S. Patent 5,645,897
 - U.S. Patent 5,705,629
 - U.S. Patent 5,840,873
 - U.S. Patent 5,843,640
- 30 U.S. Patent 5,843,650
 - U.S. Patent 5,843,651

- U.S. Patent 5,843,663
- U.S. Patent 5,846,708
- U.S. Patent 5,846,709
- U.S. Patent 5,846,717
- 5 U.S. Patent 5,846,726
 - U.S. Patent 5,846,729
 - U.S. Patent 5,846,783
 - U.S. Patent 5,849,481
 - U.S. Patent 5,849,483
- 10 U.S. Patent 5,849,486
 - U.S. Patent 5,849,487
 - U.S. Patent 5,849,497
 - U.S. Patent 5,849,546
 - U.S. Patent 5,849,547
- 15 U.S. Patent 5,851,770
 - U.S. Patent 5,851,772
 - U.S. Patent 5,853,990
 - U.S. Patent 5,853,992
 - U.S. Patent 5,853,993
- 20 U.S. Patent 5,856,092
 - U.S. Patent 5,858,652
 - U.S. Patent 5,861,244
 - U.S. Patent 5,863,732
 - U.S. Patent 5,863,753
- 25 U.S. Patent 5,866,331
 - U.S. Patent 5,866,337
 - U.S. Patent 5,866,366
 - U.S. Patent 5,900,481
 - U.S. Patent 5,905,024
- 30 U.S. Patent 5,910,407
 - U.S. Patent 5,912,124

- U.S. Patent 5,912,145
- U.S. Patent 5,912,148
- U.S. Patent 5,916,776
- U.S. Patent 5,916,779
- 5 U.S. Patent 5,919,626
 - U.S. Patent 5,919,630
 - U.S. Patent 5,922,574
 - U.S. Patent 5,925,517
 - U.S. Patent 5,925,525
- 10 U.S. Patent 5,928,862
 - U.S. Patent 5,928,869
 - U.S. Patent 5,928,870
 - U.S. Patent 5,928,905
 - U.S. Patent 5,928,906
- 15 U.S. Patent 5,929,227
 - U.S. Patent 5,932,413
 - U.S. Patent 5,932,451
 - U.S. Patent 5,935,791
 - U.S. Patent 5,935,825
- 20 U.S. Patent 5,939,291
 - U.S. Patent 5,942,391
 - U.S. Patent 5,952,174
 - U.S. Patent. 4,656,127
 - U.S. Patent 4,682,195

Araki et al., Jpn. J. Cancer Res., 84:697-702, 1993.

Ausubel et al., In: Current Protocols in Molecular Biology, Green Pub. Assoc., Inc., and John Wiley & Sons, Inc., NY, (I):2.10.3, 1989.

Borst et al., Biochim. Biophys. Acta, 1461(2):347-357, 1999

30 Borst et al. J. Natl. Cancer Inst., 92:1295-1302, 2000.

European Application 329 822

European Application 320 308

European Patent 266,032

European Patent 258,017

European Patent 50,424

5 European Patent 201,184

European Patent 237,362

European Patent 84,796

French Patent 2,650,840

Froehler et al., Nucleic Acids Res., 14(13):5399-5407, 1986.

Frohman, In: *PCR Protocols: A Guide To Methods And Applications*, Academic Press, NY, 1990.

Fuchs et al., J. Clin. Oncol., 21(5):807-814, 1993.

Great Britain Patent 2 202 328

Gupta et al., Cancer Res., 54:3723-3725, 1994.

15 Gupta et al., J. Clin. Oncol., 15:1502-1510, 1997.

Halushka et al., Nat. Genet., 22(3):239-247,1999.

Inazuka et al., Genome Res, 7(11):1094-1103, 1997.

Innis et al., Proc Natl Acad Sci USA. 85(24):9436-9440, 1988.

Iyer et al., J. Clin. Invest., 101:847-854, 1998.

20 Johnson et al., Nat. Genet., 29(2):233-237, 2001.

Kaneda et al., Cancer Res., 50:1715-1720, 1990.

Ke and Cardon, *Bioinformatics*, 19(2):287-288, 2003.

Komher, et al., Nucl. Acids. Res. 17:7779-7784, 1989.

Kuppuswamy, et al., Proc. Natl. Acad. Sci. USA, 88:1143-1147,1991.

25 Kwoh et al., Proc. Nat. Acad. Sci. USA, 86:1173, 1989.

Kwok, Annu Rev Genomics Hum Genet., 2:235-58, 2001.

Kwok and Chen, Curr Issues Mol. Biol., Apr;5(2):43-60, 2003.

Kwok et al., Genomics, 23(1):138-144, 1994.

Landegren, et al., Science, 241:1077-1080, 1988.

30 Maxam, et al., Proc. Natl. Acad. Sci. USA, 74:560, 1977.

Mullis et al., Cold Spring Harbor Symp. Quant. Biol. 51:263-273, 1986.

Negoro et al., J. Natl. Cancer Inst., 83(16):1164-1168, 1991.

Nickerson et al., Proc. Natl. Acad. Sci. USA, 87:8923-8927,1990.

Nyren et al., Anal. Biochem. 208:171-175, 1993.

Ohara et al., Proc. Natl. Acad. Sci. USA, 86:5673-5677, 1989.

5 PCT Application PCT/US87/00880

PCT Application PCT/US89/01025

PCT Application WO 88/10315

PCT Application WO 89/06700

PCT Application WO91/02087

PCT Application WO92/15712

Prezant et al., Hum. Mutat. 1:159-164, 1992.

Rothenberg et al., J. Clin. Oncol., 11(11):2194-21204, 1993.

Sambrook et al., In: Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001.

15 Sanger, et al., J. Molec. Biol., 94:441, 1975.

Sokolov, Nucl. Acids Res. 18:3671, 1990.

Sparreboom et al., Drug Resist. Update., 3:357-363, 2000.

Suzuki et al., Semin. Liver. Dis. 18:359-376, 1998.

Suzuki et al., Transporters for bile acids and organic anions, in: G.L. Amidon, W. Sadec (eds.), Membrane Transporters as Drug Targets, Kluwer Academie/Plenum Publishers, New York, 1999.

Syvanen et al., Genomics 8:684-692, 1990.

Taillon-Miller et al., Genome Res, 8(7):748-754, 1998.

Ugozzoll et al., GATA 9:107-112, 1992.

25 Vanhoefer et al., J. Clin. Oncol., 19(5):1501-18, 2001.

Walker et al., Proc. Natl. Acad. Sci. USA, 89:392-396, 1992.

WHAT IS CLAIMED IS:

- 1. A method for predicting the level of ABCC2 activity in a patient comprising:
 - a) determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 on one or both alleles is indicative of a normal level of ABCC2 activity.
- 2. The method of claim 2, wherein the sequence at position 3972 is determined for both alleles of the *ABCC2* gene.

10

5

- 3. The method of claim 2, wherein a T at position 3972 on both alleles of the *ABCC2* gene is indicative of a lower than normal level of ABCC2 activity.
- 4. The method of claim 1, further comprising obtaining a sample from the patient and using the sample to determine the sequence at position 3972.
 - 5. The method of claim 4, wherein determining the sequence at position 3972 is performed by a hybridization assay.
- 20 6. The method of claim 4, wherein determining the sequence at position 3972 is performed by an allele specific amplification assay.
 - 7. The method of claim 4, wherein determining the sequence at position 3972 is performed by a sequencing or microsequencing assay.

25

8. The method of claim 4, wherein the sample comprises buccal cells, mononuclear cells, or cancer cells.

9. The method of claim 1, wherein the sequence at position 3972 is determined by evaluating the sequence of a position in linkage disequilibrium with the sequence at position 3972.

- 10. The method of claim 9, wherein the position in linkage disequilibrium with the sequence at position 3972 is selected from the group consisting of positions -1549, -1019, -24, and +27.
- 11. The method of claim 9, wherein the sequence at position 3972 is determined by evaluating the sequence of more than one position in linkage disequilibrium with the sequence at position 3972.
- 12. The method of claim 1, further comprising administering an ABCC2 substrate to the patient.
 - 13. The method of claim 1, further comprising analyzing a clearance rate for an ABCC2 substrate.
- 20 14. The method of claim 13, wherein the substrate is selected from the group consisting of irinotecan, APC, and SN-38G.
 - 15. A method for determining dosage of an ABCC2 substrate for a patient comprising:
- 25 a) determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 on one or both

alleles indicates a higher dosage of the substrate than is indicated for a patient with a T at position 3972 in both alleles of the *ABCC2* gene.

- 16. The method of claim 15, further comprising obtaining a sample from the patient and using the sample to determine the sequence at position 3972.
 - 17. The method of claim 16, wherein determining the sequence at position 3972 is performed by a hybridization assay.
- 18. The method of claim 16, wherein determining the sequence at position 3972 is performed by an allele specific amplification assay.
 - 19. The method of claim 16, wherein determining the sequence at position 3972 is performed by a sequencing or microsequencing assay.
 - 20. The method of claim 16, wherein the sample comprises buccal cells, mononuclear cells, or cancer cells.
- 21. The method of claim 15, wherein the sequence at position 3972 is determined by evaluating the sequence of a position in linkage disequilibrium with a sequence at position 3972.
- The method of claim 15, further comprising prescribing a dosage of the substrate based on determining the sequence at position 3972 in one or both alleles of the ABCC2
 gene.

- 23. A method for predicting tumor response to an anticancer agent that is an ABCC2 substrate in a cancer patient comprising:
 - a) determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 on one or both alleles is indicative of a lower probability of an antitumor response to the anticancer agent.
- 24. The method of claim 23, wherein the sequence at position 3972 is determined for both alleles of the *ABCC2* gene.
- 25. The method of claim 24, wherein a T at position 3972 on both alleles of the *ABCC2* gene is indicative of a higher probability of an antitumor response to the anticancer agent.
- 15 26. The method of claim 23, further comprising obtaining a sample from the patient and using the sample to determine the sequence at position 3972.
 - 27. The method of claim 26, wherein determining the sequence at position 3972 is performed by a hybridization assay.
 - 28. The method of claim 26, wherein determining the sequence at position 3972 is performed by an allele specific amplification assay.
- 29. The method of claim 26, wherein determining the sequence at position 3972 is performed by a sequencing or microsequencing assay.

10

- 30. The method of claim 26, wherein the sample comprises buccal cells, mononuclear cells, or cancer cells.
- 31. The method of claim 23, wherein the sequence at position 3972 is determined by evaluating the sequence of a position in linkage disequilibrium with a sequence at position 3972.
 - 32. The method of claim 23, further comprising administering the anticancer agent to the patient.
 - 33. The method of claim 32, further comprising administering to the patient a second anticancer agent that is not an ABCC2 substrate.
- 34. The method of claim 32, further comprising prescribing a dosage of the anticancer agent based on determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene.
 - 35. A method for determining dosage of irinotecan for a patient comprising:
 - a) determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 on one or both alleles indicates a higher dosage of irinotecan than is indicated for a patient with a T at position 3972 in both alleles of the *ABCC2* gene.
- 36. The method of claim 35, further comprising obtaining a sample from the patient and using the sample to determine the sequence at position 3972.

- 37. The method of claim 36, wherein determining the sequence at position 3972 is performed by a hybridization assay.
- 38. The method of claim 36, wherein determining the sequence at position 3972 is performed by an allele specific amplification assay.
 - 39. The method of claim 36, wherein determining the sequence at position 3972 is performed by a sequencing or microsequencing assay.
- 10 40: The method of claim 36, wherein the sample comprises buccal cells, mononuclear cells, or cancer cells.
 - 41. The method of claim 35, wherein the sequence at position 3972 is determined by evaluating the sequence of a position in linkage disequilibrium with a sequence at position 3972.
 - 42. The method of claim 35, further comprising prescribing a dosage of irinotecan based on determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene.

25

- 43. A method for predicting tumor response to irinotecan in a cancer patient comprising
 - a) determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 in one or both alleles is indicative of a lower probability of an antitumor response to irinotecan.

- 44. The method of claim 43, wherein the sequence at position 3972 is determined for both alleles of the *ABCC2* gene.
- The method of claim 44, wherein a T at position 3972 on both alleles of the
 ABCC2 gene is indicative of a higher probability of an antitumor response to irinotecan.
 - 46. The method of claim 43, further comprising obtaining a sample from the patient and using the sample to determine the sequence at position 3972.
- 10 47. The method of claim 46, wherein determining the sequence at position 3972 is performed by a hybridization assay.
 - 48. The method of claim 46, wherein determining the sequence at position 3972 is performed by an allele specific amplification assay.
 - 49. The method of claim 46, wherein determining the sequence at position 3972 is performed by a sequencing or microsequencing assay.
- 50. The method of claim 46, wherein the sample comprises buccal cells, mononuclear cells, or cancer cells.
 - 51. The method of claim 43, wherein the sequence at position 3972 is determined by evaluating the sequence of a position in linkage disequilibrium with a sequence at position 3972.

52. The method of claim 43, further comprising administering irinotecan to the patient.

25391509.1

15

53. The method of claim 52, further comprising prescribing a dosage of irinotecan based on determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene.

5

- 54. A method for predicting a clearance rate for irinotecan in a patient comprising
 - a) determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 in one or both alleles is indicative of a normal clearance rate for irinotecan.

10

- 55. The method of claim 54, wherein the sequence at position 3972 is determined for both alleles of the *ABCC2* gene.
- 56. The method of claim 55, wherein a T at position 3972 on both alleles of the ABCC2 gene is indicative of a lower than normal clearance rate for irinotecan.
 - 57. The method of claim 54, further comprising obtaining a sample from the patient and using the sample to determine the sequence at position 3972.
- 58. The method of claim 57, wherein determining the sequence at position 3972 is performed by a hybridization assay.
 - 59. The method of claim 57, wherein determining the sequence at position 3972 is performed by an allele specific amplification assay.

25

60. The method of claim 57, wherein determining the sequence at position 3972 is performed by a sequencing or microsequencing assay.

- 61. The method of claim 57, wherein the sample comprises buccal cells, mononuclear cells, or cancer cells.
- 5 62. The method of claim 54, wherein the sequence at position 3972 is determined by evaluating the sequence of a position in linkage disequilibrium with a sequence at position 3972.
- 63. The method of claim 54, further comprising administering irinotecan to the patient.
 - 64. The method of claim 62, further comprising prescribing a dosage of irinotecan based on determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene.

- 65. A kit for predicting a clearance rate for an ABCC2 substrate in a patient comprising a nucleic acid for determining the sequence at position 3972 in an ABCC2 gene.
- 20 66. The kit of claim 65, wherein the nucleic acid is a primer for amplifying the sequence at position 3972 in the *ABCC2* gene.
 - 67. The kit of claim 65, wherein the nucleic acid is a specific hybridization probe for detecting the sequence at position 3972 in the *ABCC2* gene.

25

68. The kit of claim 67, wherein the specific hybridization probe is comprised in an oligonucleotide array or microarray.

ABSTRACT

The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2 gene and correlating these polymorphisms with activity levels of ABCC2 and making evaluations regarding the effect on ABCC2 substrates, particularly those substrates that are drugs. In addition, there are methods and compositions of evaluating the risk of an individual for developing toxicity or adverse event(s) to an ABCC2 substrate. In some embodiments, the invention concerns methods and compositions for determining the presence or absence of *ABCC2* 3972C>T variant and predicting or anticipating the level of activity of ABCC2 and determining dosages of an ABCC2 drug substrate, such as irinotecan, in a patient. Such methods and compositions can be used to evaluate whether irinotecan-based therapy, or therapy involving other ABCC2 substrates, may pose toxicity problems if given to a particular patient or predicting their efficacy. Alterations in suggested therapy may ensue based on genotyping results.

5

SEQUENCE LISTING

<110	II KI	ATAII NNOCI ROETI NDEVI	ENTI Z, D	, FEI EANN	DERIO A L.	CO										
<120					OMPO:			RELA'	TING	TO T	THE :	PHARI	MACO	GENE'	TICS	
<130)> AI	R C D : 4	405U	SP1												
		NKNOV 004-0		5												
<160)> 3															
<170)> Pa	atent	tIn V	Ver.	2.1											
<210 <211 <212 <213	.> 48 !> Di		sapio	ens												
<220 <221 <222	> CI		. (46'	75)												
<400	> 1															
		eat d	attte	atte	ra da	caca	atc	r ago	aato	ato	a cto	a dad	7 aac	1 tt/	r tac	55
		gt d	cttt	gttc	ca ga	acgca	agtco	c ag	gaato	Met	-		-	s Phe	c tgc e Cys 5	55
	ccgo tct	act	ttt	tgg	aat	tcc	tca	ttc	ctg	Mei gac	Lei l agt	ı Gli	ı Lys	s Phe	e Cys 5 gac	103
gcgg	tct Ser	act Thr	ttt Phe 10 tgt	tgg Trp	aat Asn gag	tcc Ser	tca Ser	ttc Phe 15 gtt	ctg Leu ctg	gac Asp	agt Ser	ccg Pro	gag Glu 20	gca Ala	gac Asp	
aac Asn ctg Leu	tct Ser cca Pro	act Thr ctt Leu 25	ttt Phe 10 tgt Cys	tgg Trp ttt Phe	aat Asn gag Glu	tcc Ser caa Gln	tca Ser act Thr 30	ttc Phe 15 gtt Val	ctg Leu ctg Leu	gac Asp gtg Val	agt Ser tgg Trp	ccg Pro att Ile 35	gag Glu 20 ccc Pro	gca Ala ttg Leu	gac Asp ggc Gly	103
aac Asn ctg Leu	tct Ser CCa Pro Cta Leu 40	act Thr ctt Leu 25 tgg Trp	ttt Phe 10 tgt Cys ctc Leu	tgg Trp ttt Phe ctg Leu	aat Asn gag Glu gcc Ala	tcc Ser caa Gln ccc Pro 45	tca ser act Thr 30 tgg Trp	ttc Phe 15 gtt Val cag Gln	ctg Leu ctg Leu ctt	gac Asp gtg Val ctc Leu	agt Ser tgg Trp cac His	ccg Pro att Ile 35 gtg Val	gag Glu 20 ccc Pro tat Tyr	gca Ala ttg Leu aaa Lys	gac Asp ggc Gly tcc Ser	103
aac Asn ctg Leu ttc Phe	tct Ser CCa Pro Cta Leu 40 acc Thr	act Thr ctt Leu 25 tgg Trp aag Lys	ttt Phe 10 tgt Cys ctc Leu aga Arg	tgg Trp ttt Phe ctg Leu tcc Ser	aat Asn gag Glu gcc Ala tct Ser 60	tcc Ser caa Gln ccc Pro 45 acc Thr	tca Ser act Thr 30 tgg Trp acc Thr	ttc Phe 15 gtt Val cag Gln aaa Lys	ctg Leu ctg Leu ctt Leu ctc	gac Asp gtg Val ctc Leu tat Tyr 65 ata	t Len agt Ser tgg Trp cac His 50 ctt Leu gag	ccg Pro att Ile 35 gtg Val gct Ala	gag Glu 20 ccc Pro tat Tyr aag Lys	gca Ala ttg Leu aaa Lys cag	gac Asp ggc Gly tcc Ser gta Val 70	103 153

		_								_	_	_	ctg Leu			391
	_	_			_	_	_						ctg Leu			439
				_			_						cag Gln		_	487
					_		_					_	tac Tyr		_	535
_								_		_		_	atc Ile 180			583
_			-										tcc Ser		_	631
		_	-	_				-			-	-	atc Ile		_	679
										Asp			gaa Glu			727
215	V -1	-1-	2		220					225					230	
215 gaa	gag	atg	aaa	acc	aag				_	aag		_	acg Thr		atg	775
gaa Glu aag	gag Glu aga	atg Met gag	aaa Lys ctg	acc Thr 235 cag	aag Lys aaa	Thr gcc	Leu agg	Val	Ser 240 gca	aag Lys ctc	Phe cag	Glu	_	His 245 cag	atg Met gag	775 823
gaa Glu aag Lys	gag Glu aga Arg	atg Met gag Glu	aaa Lys ctg Leu 250	acc Thr 235 cag Gln	aag Lys aaa Lys	Thr gcc Ala tct	Leu agg Arg	Val cgg Arg 255	Ser 240 gca Ala agg	aag Lys ctc Leu	Phe cag Gln cct	Glu aga Arg	Thr cgg Arg	His 245 cag Gln aac	atg Met gag Glu aag	
gaa Glu aag Lys aag	gag Glu aga Arg agc ser	atg Met gag Glu tcc Ser 265	aaa Lys ctg Leu 250 cag Gln	acc Thr 235 cag Gln cag Gln	aag Lys aaa Lys aac Asn	Thr gcc Ala tct Ser	agg Arg gga Gly 270	Val cgg Arg 255 gcc Ala	ser 240 gca Ala agg Arg	aag Lys ctc Leu ctg	Phe cag Gln cct Pro	Glu aga Arg ggc Gly 275 gat	Thr cgg Arg 260 ttg	His 245 cag Gln aac Asn	atg Met gag Glu aag Lys	823
gaa Glu aag Lys aag Lys	gag Glu aga Arg agc Ser cag Gln 280 aaa	atg Met gag Glu tcc Ser 265 agt Ser	aaa Lys ctg Leu 250 cag Gln caa Gln	acc Thr 235 cag Gln cag Gln agc Ser	aag Lys aaa Lys aac Asn caa Gln	Thr gcc Ala tct Ser gat Asp 285 acc	Leu agg Arg gga Gly 270 gcc Ala	Val cgg Arg 255 gcc Ala ctt Leu	Ser 240 gca Ala agg Arg gtc Val	aag Lys ctc Leu ctg Leu ctg	Phe cag Gln cct Pro gaa Glu 290 cca	Glu aga Arg ggc Gly 275 gat Asp	Thr cgg Arg 260 ttg Leu gtt	His 245 cag Gln aac Asn gaa Glu	atg Met gag Glu aag Lys aag Lys	823 871

	ctg Leu	_				_			_			_		_	_	1063
	aaa Lys															1111
	gga Gly 360			_	_							_			_	1159
	ttc Phe															1207
	gta Val			_		_	_		_		_	_	_	_		1255
	tcc Ser		_	_		_				_		_				1303
_	atg Met			_	_	_	_		_	_					_	1351
	atg Met 440															1399
	tgg Trp											_				1447
	ctt Leu															1495
	cag Gln															1543
	gag Glu															1591
	tca Ser 520															1639
	ctg Leu	_	_		_			_	_	_	_			_		1687
cag	tta	act	cca	gtc	ctg	gta	tct	gtg	gtc	aca	ttt	tct	gtt	tat	gtc	1735

Gln	Leu	Thr	Pro	Val 555	Leu	Val	Ser	Val	Val 560	Thr	Phe	Ser	Val	Tyr 565	Val	
				aac Asn												1783
				aat Asn		_	_				_					1831
				atg Met												1879
				gly ggg												1927
				aaa Lys 635												1975
_		_	_	gaa Glu	_		_	_	_			_	_		_	2023
_				gtg Val	_					_						2071
				gcc Ala												2119
				ggc Gly												2167
				ata Ile 715												2215
				cag Gln												2263
				cct Pro												2311
				ggg Gly												2359
				tta Leu												2407

775	780	785	790
		ttt aat aag gtc ttg g Phe Asn Lys Val Leu 6 800	_
		ctc ttg gtt aca cat a Leu Leu Val Thr His S 820	
		gta gtt ctg ggg aat g Val Val Leu Gly Asn G 835	
		ctc ctg gcc aaa aaa g Leu Leu Ala Lys Lys G 850	
		aga cat aca ggc cct g Arg His Thr Gly Pro G 865	
		gaa gaa gac gat gac t Glu Glu Asp Asp Asp T 880	
		gaa gat gca gcc tcc a Glu Asp Ala Ala Ser I 900	
		aca ctt agc cgc agt t Thr Leu Ser Arg Ser S 915	
		aga aac tcc ttg aaa a Arg Asn Ser Leu Lys T 930	
		gaa cta gtg aaa gga c Glu Leu Val Lys Gly G 945	
	-	gga aag gtg aag ttc t Gly Lys Val Lys Phe S 960	
		ttg ttt tcg ata ttc t Leu Phe Ser Ile Phe F 980	
		gct ttt att gga tcc a Ala Phe Ile Gly Ser A 995	
		aaa atc ttc aat agc a Lys Ile Phe Asn Ser T 1010	

1015			gtt gga gtc tac Val Gly Val Tyn 1025		3127
		Phe Val Phe	ata gca cat tto Ile Ala His Pho .040		3175
Phe Gly Phe V			ttg cac aag caa Leu His Lys Glr		3223
			ttt gac aca aca Phe Asp Thr Thi 1075	r Pro Thr Gly	3271
	Asn Arg Phe		att tcc aca gtg Ile Ser Thr Val 1090		3319
			aca tgc ttc ctc Thr Cys Phe Let 1105		3367
•	-	Cys Met Ala	act cct gtc tto Thr Pro Val Pho .120		3415
Val Ile Pro I			tct gtt cag ato Ser Val Gln Met		3463
tot acc toc o	cgc cag ctg				
	Arg Gln Leu		Asp Ser Val Thi	_	3511
Ser Thr Ser A	cac ttc agc His Phe Ser	Arg Arg Leu 1150 gag acc gta	Asp Ser Val Th	r Arg Ser Pro	3511
Ser Thr Ser A 1145 atc tac tct of Ile Tyr Ser A 1160 gcc ttt gag of	cac ttc agc His Phe Ser	Arg Arg Leu 1150 gag acc gta Glu Thr Val 1165 cga ttt ctg	Asp Ser Val Thi 1159 tca ggt ttg cca Ser Gly Leu Pro	a gtt atc cgt Val Ile Arg	
Ser Thr Ser A 1145 atc tac tct of Ile Tyr Ser A 1160 gcc ttt gag of Ala Phe Glu A 1175 gac acc aac of	cac ttc agc His Phe Ser Cac cag cag His Gln Gln 1180	Arg Arg Leu 1150 gag acc gta Glu Thr Val 1165 cga ttt ctg Arg Phe Leu gtc ttt tcc Val Phe Ser	Asp Ser Val Thi 1159 tca ggt ttg cca Ser Gly Leu Pro 1170 aaa cac aat gag Lys His Asn Glu	a gtt atc cgt val Ile Arg gtg agg att Val Arg Ile 1190 c aac agg tgg	3559
Ser Thr Ser A 1145 atc tac tct c Ile Tyr Ser B 1160 gcc ttt gag c Ala Phe Glu B 1175 gac acc aac c Asp Thr Asn c ctt gca att c Leu Ala Ile A	cac ttc agc His Phe Ser cac cag cag His Gln Gln 1180 cag aaa tgt Gln Lys Cys 1195	Arg Arg Leu 1150 gag acc gta Glu Thr Val 1165 cga ttt ctg Arg Phe Leu gtc ttt tcc Val Phe Ser ctg gtt ggg	Asp Ser Val Thr 1155 tca ggt ttg cca Ser Gly Leu Pro 1170 aaa cac aat gag Lys His Asn Glu 1185 tgg atc acc tcc Trp Ile Thr Ser	a gtt atc cgt Val Ile Arg gtg agg att Val Arg Ile 1190 c aac agg tgg r Asn Arg Trp 1205	3559 3607

ggc ttt gtt ctg tcc	aat gca ctc aa	at atc aca caa ac	c ctg aac tgg 379	99
Gly Phe Val Leu Ser 1240	_			
ctg gtg agg atg aca Leu Val Arg Met Thr 1255				47
cga ata act gag tac Arg Ile Thr Glu Tyr 1275				95
gat aag agg cct ccg Asp Lys Arg Pro Pro 1290		ro Ser Lys Gly Ly	_	43
aac aac tac caa gtg Asn Asn Tyr Gln Val 1305			l Val Leu Arg	91
ggg atc act tgt gac Gly Ile Thr Cys Asp 1320				39
agg aca gga gct gga Arg Thr Gly Ala Gly 1335				87
tta gag gct gcc ggt Leu Glu Ala Ala Gly 1355				35
tcc att ggg ctc cac Ser Ile Gly Leu His 1370		lu Lys Leu Thr Il		83
gac ccc atc ctg ttc Asp Pro Ile Leu Phe 1385		eu Arg Met Asn Le	Asp Pro Phe	31
aac aac tac tca gat Asn Asn Tyr Ser Asp 1400				79
ctc aag tct ttt gtg Leu Lys Ser Phe Val 1415				27
aca gag gct ggt ggc Thr Glu Ala Gly Gly 1435				75
ctg ggc agg gct ctg Leu Gly Arg Ala Leu 1450		er Lys Ile Leu Va		23
gcc act gct gcg gtg	gat cta gag a	ca gac aac ctc at	c cag acg acc 44'	71

Ala		Ala 1465	Ala	Val	Asp		Glu 1470	Thr	Asp	Asn	Leu	Ile 1475	Gln	Thr	Thr	
Ile					Ala					Ile	acc Thr 1490					4519
	His			Met					Val		gtc Val			Asn		4567
			Glu					Glu			cta Leu		Ile			4615
		Tyr					Glu				gag Glu	Asn				4663
	Lys		tag	caga	aggo	ccc o	catgg	ggtta	ag aa	aaagg	gacta	a taa	agaat	taat		4715
ttct	tatt	ta a	atttt	attt	t tt	ataa	aaata	a cag	gaata	acat	acaa	aagt	gt g	gtata	aaatg	4775
tac	gttt	caa a	aaaag	ggata	aa gt	gaad	cacco	ato	gaaco	ctac	taco	ccag	gtt a	aagaa	aaataa	4835
atgt	ccaco	cag g	gtact	tgag	ga aa	accc	ctcga	ttg	3							4868
<21)> 2 > 15	545														
	2> PF 3> Ho		sapie	ens												
<213	2> PF 3> Ho		sapie	ens												
<213	2> PF 3> Ho 0> 2	omo s	_		Cys	Asn	Ser	Thr	Phe	Trp	Asn	Ser	Ser	Phe	Leu	
<213 <400 Met 1	2> PF 3> Ho 0> 2 Leu	omo s	Lys	Phe 5				Leu	10		Asn Glu		Thr	· 15		
<213 <400 Met 1 Asp	2> PB 3> Ho 0> 2 Leu Ser	Glu Pro Ile	Lys Glu 20	Phe 5 Ala	Asp	Leu	Pro Leu	Leu 25	10 Cys	Phe		Gln Pro	Thr 30	·15 Val	Leu	
<213 <400 Met 1 Asp	2> PR 3> Ho 0> 2 Leu Ser Trp	Glu Pro Ile 35	Lys Glu 20 Pro	Phe 5 Ala Leu	Asp Gly	Leu Phe Arg	Pro Leu 40	Leu 25 Trp	10 Cys .Leu	Phe Leu	Glu Ala Ser	Gln Pro 45	Thr 30 Trp	·15 Val Gln	Leu Leu	
<213 <400 Met 1 Asp Val Leu	2> PR 3> Ho 0> 2 Leu Ser Trp His 50	Glu Pro Ile 35 Val	Lys Glu 20 Pro	Phe 5 Ala Leu Lys	Asp Gly Ser	Leu Phe Arg 55	Pro Leu 40 Thr	Leu 25 Trp Lys	10 Cys .Leu Arg	Phe Leu Ser	Glu Ala	Gln Pro 45 Thr	Thr 30 Trp Thr	· 15 Val Gln Lys	Leu Leu Leu Ala	
<213 <400 Met 1 Asp Val Leu Tyr 65	2> PR 3> Ho 0> 2 Leu Ser Trp His 50 Leu	Glu Pro Ile 35 Val	Lys Glu 20 Pro Tyr Lys	Phe 5 Ala Leu Lys Gln	Asp Gly Ser Val	Leu Phe Arg 55 Phe	Pro Leu 40 Thr	Leu 25 Trp Lys Gly	10 Cys Leu Arg	Phe Leu Ser Leu 75	Glu Ala Ser 60	Gln Pro 45 Thr	Thr 30 Trp Thr	·15 Val Gln Lys Ala	Leu Leu Leu Ala 80	
<400 Met 1 Asp Val Leu Tyr 65 Ile	2> PR 3> Ho 0> 2 Leu Ser Trp His 50 Leu	Glu Pro Ile 35 Val Ala Leu	Lys Glu 20 Pro Tyr Lys Ala	Phe 5 Ala Leu Lys Gln Leu 85	Asp Gly Ser Val 70 Val	Leu Phe Arg 55 Phe Leu	Pro Leu 40 Thr Val	Leu 25 Trp Lys Gly Glu	10 Cys Leu Arg Phe Asp 90	Phe Leu Ser Leu 75 Ser	Glu Ala Ser 60 Leu	Gln Pro 45 Thr Ile Gln	Thr 30 Trp Thr Leu Ala	·15 Val Gln Lys Ala Thr 95	Leu Leu Leu Ala 80 Val	
<400 Met 1 Asp Val Leu Tyr 65 Ile	2> PR 3> Ho 0> 2 Leu Ser Trp His 50 Leu Glu	Glu Pro Ile 35 Val Ala Leu Val	Lys Glu 20 Pro Tyr Lys Ala Arg 100	Phe 5 Ala Leu Lys Gln Leu 85 Tyr	Asp Gly Ser Val 70 Val	Leu Phe Arg 55 Phe Leu Asn	Pro Leu 40 Thr Val Thr	Leu 25 Trp Lys Gly Glu Ser 105	10 Cys Leu Arg Phe Asp 90 Leu	Phe Leu Ser Leu 75 Ser Tyr	Glu Ala Ser 60 Leu Gly	Gln Pro 45 Thr Ile Gln Gly	Thr 30 Trp Thr Leu Ala Thr 110	Val Gln Lys Ala Thr 95 Trp	Leu Leu Leu Ala 80 Val Leu	
<400 Met 1 Asp Val Leu Tyr 65 Ile Pro	2> PR 3> Ho 0> 2 Leu Ser Trp His 50 Leu Glu Ala	Glu Pro Ile 35 Val Ala Leu Val Leu 115	Lys Glu 20 Pro Tyr Lys Ala Arg 100 Leu	Phe 5 Ala Leu Lys Gln Leu 85 Tyr	Asp Gly Ser Val 70 Val Thr	Leu Phe Arg 55 Phe Leu Asn Tyr	Pro Leu 40 Thr Val Thr Pro Ser 120	Leu 25 Trp Lys Gly Glu Ser 105 Arg	10 Cys Leu Arg Phe Asp 90 Leu Gln	Phe Leu Ser Leu 75 Ser Tyr	Glu Ala Ser 60 Leu Gly Leu	Gln Pro 45 Thr Ile Gln Gly Val 125	Thr 30 Trp Thr Leu Ala Thr 110 Gln	· 15 Val Gln Lys Ala Thr 95 Trp Lys	Leu Leu Ala 80 Val Leu Asn	
<400 Met 1 Asp Val Leu Tyr 65 Ile Pro Leu Ser	2> PR 3> Ho 0> 2 Leu Ser Trp His 50 Leu Glu Ala Val	Glu Pro Ile 35 Val Ala Leu Val Leu 115 Phe	Lys Glu 20 Pro Tyr Lys Ala Arg 100 Leu Leu	Phe 5 Ala Leu Lys Gln Leu 85 Tyr Ile Ser	Asp Gly Ser Val 70 Val Thr Gln Leu	Leu Phe Arg 55 Phe Leu Asn Tyr Phe 135	Pro Leu 40 Thr Val Thr Pro Ser 120 Trp	Leu 25 Trp Lys Gly Glu Ser 105 Arg	10 Cys Leu Arg Phe Asp 90 Leu Gln	Phe Leu Ser Leu 75 Ser Tyr Trp Ser	Glu Ala Ser 60 Leu Gly Leu Cys Ile	Gln Pro 45 Thr Ile Gln Gly Val 125 Leu	Thr 30 Trp Thr Leu Ala Thr 110 Gln	Oln Lys Ala Thr 95 Trp Lys Gly	Leu Leu Ala 80 Val Leu Asn Thr	

				165					170					175	
Leu	Ile	Leu	Ile 180		Ser	Ala	Phe	Ser 185	_	Asn	Asn	Glu	Ser 190		Asn
Asn	Pro	Ser 195		Ile	Ala	Ser	Phe 200	Leu	Ser	Ser	Ile	Thr 205	Tyr	Ser	Trp
Tyr	Asp 210	Ser	Ile	Ile	Leu	Lys 215	Gly	Tyr	Lys	Arg	Pro 220	Leu	Thr	Leu	Glu
225		_			Asp 230					235	_				240
_				245	Met				250					255	
		_	260		Glu	-		265					270		_
		275			Lys		280					285			
	290				Lys	295					300				
305					Leu 310					315					320
				325	Phe				330					335	
			340		Leu			345					350		
_		355	_		Trp		360			_		365			
	370				Gln	375					380				
385		_			Val 390					395					400
_	_	_		405	Thr				410		_	_		415	
	_		420		Asn			425		_			430		
_		435			Met		440		_			445			
Val	Leu 450	Ser	Ile	Phe	Phe	Leu 455	Trp	Arg	Glu	Leu	Gly 460	Pro	Ser	Val	Leu
465	_				Met 470					475					480
		_		485	Thr				490					495	
_	_		500		Met			505			_		510		
Ī	_	515					520					525			Leu
Ī	530	_			Lys	535					540				_
Val 545	Val	Ile	Phe	Val	Phe 550	GIn	Leu	Thr	Pro	Val 555	Leu	Val	Ser	Val	Val 560
	Phe	Ser	Val	Tyr 565	Val	Leu	Val	Asp	Ser 570	Asn	Asn	Ile	Leu	Asp 575	Ala
Gln	Lys	Ala	Phe 580	Thr	Ser	Ile	Thr	Leu 585	Phe	Asn	Ile	Leu	Arg 590	Phe	Pro
		595					600					605			Val
Ser	Thr 610	Glu	Arg	Leu	Glu	Lys 615	Tyr	Leu	Gly	Gly	Asp 620	Asp	Leu	Asp	Thr

Ser Ala Ile Arg His Asp Cys Asn Phe Asp Lys Ala Met Gln Phe Ser Glu Ala Ser Phe Thr Trp Glu His Asp Ser Glu Ala Thr Val Arg Asp Val Asn Leu Asp Ile Met Ala Gly Gln Leu Val Ala Val Ile Gly Pro Val Gly Ser Gly Lys Ser Ser Leu Ile Ser Ala Met Leu Gly Glu Met Glu Asn Val His Gly His Ile Thr Ile Lys Gly Thr Thr Ala Tyr Val Pro Gln Gln Ser Trp Ile Gln Asn Gly Thr Ile Lys Asp Asn Ile Leu Phe Gly Thr Glu Phe Asn Glu Lys Arg Tyr Gln Gln Val Leu Glu Ala Cys Ala Leu Leu Pro Asp Leu Glu Met Leu Pro Gly Gly Asp Leu Ala Glu Ile Gly Glu Lys Gly Ile Asn Leu Ser Gly Gly Gln Lys Gln Arg Ile Ser Leu Ala Arg Ala Thr Tyr Gln Asn Leu Asp Ile Tyr Leu Leu Asp Asp Pro Leu Ser Ala Val Asp Ala His Val Gly Lys His Ile Phe Asn Lys Val Leu Gly Pro Asn Gly Leu Leu Lys Gly Lys Thr Arg Leu Leu Val Thr His Ser Met His Phe Leu Pro Gln Val Asp Glu Ile Val Val Leu Gly Asn Gly Thr Ile Val Glu Lys Gly Ser Tyr Ser Ala Leu Leu Ala Lys Lys Gly Glu Phe Ala Lys Asn Leu Lys Thr Phe Leu Arg His Thr Gly Pro Glu Glu Glu Ala Thr Val His Asp Gly Ser Glu Glu Glu Asp Asp Asp Tyr Gly Leu Ile Ser Ser Val Glu Glu Ile Pro Glu Asp Ala Ala Ser Ile Thr Met Arg Arg Glu Asn Ser Phe Arg Arg Thr Leu Ser Arg Ser Ser Arg Ser Asn Gly Arg His Leu Lys Ser Leu Arg Asn Ser Leu Lys Thr Arg Asn Val Asn Ser Leu Lys Glu Asp Glu Glu Leu Val Lys Gly Gln Lys Leu Ile Lys Lys Glu Phe Ile Glu Thr Gly Lys Val Lys Phe Ser Ile Tyr Leu Glu Tyr Leu Gln Ala Ile Gly Leu Phe Ser Ile Phe Phe Ile Ile Leu Ala Phe Val Met Asn Ser Val Ala Phe Ile Gly Ser Asn Leu Trp Leu Ser Ala Trp Thr Ser Asp Ser Lys Ile Phe Asn Ser Thr Asp Tyr Pro Ala Ser Gln Arg Asp Met Arg Val Gly Val Tyr Gly Ala Leu Gly Leu Ala Gln Gly Ile Phe Val Phe Ile Ala His Phe Trp Ser Ala Phe Gly Phe Val His Ala Ser Asn Ile Leu His Lys Gln Leu Leu Asn Asn Ile Leu Arg Ala Pro Met Arg Phe Phe Asp Thr Thr Pro Thr Gly Arg Ile Val Asn Arg Phe Ala Gly Asp Ile

1075	1080	10	85
Ser Thr Val Asp Asp '			
1090	1095	1100	
Cys Phe Leu Gly Ile			
	110	1115	1120
Pro Val Phe Thr Ile :		Leu Gly 11e 1. 1130	1135
Val Gln Met Phe Tyr			
1140	1145		1150
Ser Val Thr Arg Ser	Pro Ile Tyr Ser	His Phe Ser G	lu Thr Val Ser
1155	1160	11	
Gly Leu Pro Val Ile	_		rg Phe Leu Lys
1170 His Asn Glu Val Arg	1175 Tle Non Thr Non	1180	al Dhe Ger Trn
_	190	1195	1200
Ile Thr Ser Asn Arg			
1205	_	.210	1215
Leu Thr Val Phe Phe	Ser Ala Leu Met	Met Val Ile T	
1220	1225		1230
Leu Ser Gly Asp Thr	Val Gly Phe Val 1240	Leu Ser Asn A	
1235 Thr Gln Thr Leu Asn '			- -
1250	1255	1260	ia iic dia iii
Asn Ile Val Ala Val		Glu Tyr Thr L	ys Val Glu Asn
	270	1275	1280
Glu Ala Pro Trp Val			= =
1285 Lys Gly Lys Ile Gln		1290 Cla Val Ara T	1295
1300	1305	GIII VAI AIG I	1310
Leu Asp Leu Val Leu A		Cys Asp Ile G	
1315	1320	13	_
Lys Ile Gly Val Val			er Ser Leu Thr
1330	1335	1340	l. Tla Tla Tla
Asn Cys Leu Phe Arg 1	lle Leu Glu Ala 350	1355	in lie lie lie 1360
Asp Gly Val Asp Ile			
1365	-	1370	1375
Leu Thr Ile Ile Pro	Gln Asp Pro Ile	Leu Phe Ser G	ly Ser Leu Arg
1380	1385		1390
Met Asn Leu Asp Pro			
1395 Ala Leu Glu Leu Ala 1	1400 His Leu Lys Ser	Dhe Val Ala S	
1410	1415		er bed oin bed
Gly Leu Ser His Glu		1420	
	vai inr Giu Ala		eu Ser Ile Gly
1425 1	430	Gly Gly Asn L 1435	1440
1425 1. Gln Arg Gln Leu Leu	430 Cys Leu Gly Arg	Gly Gly Asn L 1435 Ala Leu Leu A	1440 rg Lys Ser Lys
1425 1425 1445	430 Cys Leu Gly Arg 1	Gly Gly Asn L 1435 Ala Leu Leu A 450	1440 rg Lys Ser Lys 1455
1425 10 Gln Arg Gln Leu Leu (1445 Ile Leu Val Leu Asp (1	430 Cys Leu Gly Arg I Glu Ala Thr Ala	Gly Gly Asn L 1435 Ala Leu Leu A 450	1440 rg Lys Ser Lys 1455 eu Glu Thr Asp
1425 1425 1445	430 Cys Leu Gly Arg Glu Ala Thr Ala 1465	Gly Gly Asn L 1435 Ala Leu Leu A 450 Ala Val Asp L	1440 rg Lys Ser Lys 1455 eu Glu Thr Asp 1470
1425 1. Gln Arg Gln Leu Leu (1445 Ile Leu Val Leu Asp (1460 Asn Leu Ile Gln Thr (1475	430 Cys Leu Gly Arg Glu Ala Thr Ala 1465 Thr Ile Gln Asn 1480	Gly Gly Asn L 1435 Ala Leu Leu A 450 Ala Val Asp L Glu Phe Ala H	1440 rg Lys Ser Lys 1455 eu Glu Thr Asp 1470 is Cys Thr Val
1425 16 Gln Arg Gln Leu Leu 6 1445 Ile Leu Val Leu Asp 6 1460 Asn Leu Ile Gln Thr 6 1475 Ile Thr Ile Ala His 2	430 Cys Leu Gly Arg Glu Ala Thr Ala 1465 Thr Ile Gln Asn 1480 Arg Leu His Thr	Gly Gly Asn L 1435 Ala Leu Leu A 450 Ala Val Asp L Glu Phe Ala H 14 Ile Met Asp S	1440 rg Lys Ser Lys 1455 eu Glu Thr Asp 1470 is Cys Thr Val
1425 1.6 Gln Arg Gln Leu Leu (1445) Ile Leu Val Leu Asp (1460) Asn Leu Ile Gln Thr (1475) Ile Thr Ile Ala His (1490)	430 Cys Leu Gly Arg Glu Ala Thr Ala 1465 Thr Ile Gln Asn 1480 Arg Leu His Thr	Gly Gly Asn L 1435 Ala Leu Leu A 450 Ala Val Asp L Glu Phe Ala H 14 Ile Met Asp S 1500	1440 rg Lys Ser Lys 1455 eu Glu Thr Asp 1470 is Cys Thr Val 85 er Asp Lys Val
1425 16 Gln Arg Gln Leu Leu 1445 Ile Leu Val Leu Asp 1460 Asn Leu Ile Gln Thr 1475 Ile Thr Ile Ala His 1490 Met Val Leu Asp Asn 6	430 Cys Leu Gly Arg Glu Ala Thr Ala 1465 Thr Ile Gln Asn 1480 Arg Leu His Thr 1495 Gly Lys Ile Ile	Gly Gly Asn L 1435 Ala Leu Leu A 450 Ala Val Asp L Glu Phe Ala H 14 Ile Met Asp S 1500 Glu Cys Gly S	1440 rg Lys Ser Lys 1455 eu Glu Thr Asp 1470 is Cys Thr Val 85 er Asp Lys Val
1425 16 Gln Arg Gln Leu Leu 1445 Ile Leu Val Leu Asp 1460 Asn Leu Ile Gln Thr 1475 Ile Thr Ile Ala His 1490 Met Val Leu Asp Asn 6	430 Cys Leu Gly Arg Glu Ala Thr Ala 1465 Thr Ile Gln Asn 1480 Arg Leu His Thr 1495 Gly Lys Ile Ile 510	Gly Gly Asn L 1435 Ala Leu Leu A 450 Ala Val Asp L Glu Phe Ala H 14 Ile Met Asp S 1500 Glu Cys Gly S 1515	1440 rg Lys Ser Lys 1455 eu Glu Thr Asp 1470 is Cys Thr Val 85 er Asp Lys Val er Pro Glu Glu 1520
1425 14 Gln Arg Gln Leu Leu 1445 Ile Leu Val Leu Asp 1460 Asn Leu Ile Gln Thr 1475 Ile Thr Ile Ala His 1490 Met Val Leu Asp Asn 1505	430 Cys Leu Gly Arg Glu Ala Thr Ala 1465 Thr Ile Gln Asn 1480 Arg Leu His Thr 1495 Gly Lys Ile Ile 510 Gly Pro Phe Tyr	Gly Gly Asn L 1435 Ala Leu Leu A 450 Ala Val Asp L Glu Phe Ala H 14 Ile Met Asp S 1500 Glu Cys Gly S 1515	1440 rg Lys Ser Lys 1455 eu Glu Thr Asp 1470 is Cys Thr Val 85 er Asp Lys Val er Pro Glu Glu 1520

Ile Glu Asn Val Asn Ser Thr Lys Phe 1540 1545

<210>	3						
<211>	184			•			
<212>	DNA						
<213>	Homo	sapiens					
<400>	3						
aactta	acttc	tcatcttgtc	tccttgccag	gcaccctggg	tgactgataa	gaggcctccg	60
ccagat	tggc	ccagcaaagg	caagatccag	tttaacaact	accaagtgcg	gtaccgacct	120
gagcto ggag	gatc	tggtcctcag	agggatcact	tgtgacatcg	gtagcatgga	gaaggtaggt	180 184




FIG. 1




FIG. 2

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c). Express Mail Label No. EV 414834592 US

INVENTOR(S)						
Given Name (first and middle [if any])	Family Name or Surname	(City	Residence and either State or Foreigr	n Country)		
Mark J.	Ratain	Chicago	o, IL			
Additional inventors are being named on the	Additional inventors are being named on the 1 separately numbered sheets attached hereto					
	LE OF THE INVENTION (500 ci	naracters max)		26. PT		
Methods and Compositions Relating to the Pharmacogenetics of ABCC2 Gene Variants						
Direct all correspondence to: CORRESPONDENCE ADDRESS						
Customer Number:	32425			17548 60/ 5		
OR		<u> </u>				
Firm or Individual Name						
Address						
Address		<u></u>				
City	State		Zip			
Country	Telep	hone	Fax			
ENCLOSED APPLICATION PARTS (check all that apply)						
Specification Number of Pages 57 + 12-pg. sequence listing CD(s), Number 1						
Drawing(s) Number of Sheets 2 Other (specify) Statement re: sequence listing						
Application Date Sheet. See 37 CFR 1.79	6		(w/paper copy & disk);	postcard)		
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT						
Applicant claims small entity status. See	37 CFR 1.27		FILING FEE			
			Amount (\$)			
A check or money order is enclosed to cover the filing fees.						
The Director is herby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 50-1212			80.00			
Payment by credit card. Form PTO-2038 is attached.						
The invention was made by an agency of the United States Government.	Inited States Government or under a	a contract with an age	ency of the			
No.						
Yes, the name of the U.S. Government agency and the Government contract number are: National Institutes of Health, Grant Number GM61393						
Downstill, outputted	[Page 1 of 2]	Date March	5. 2004			
Respectfully submitted,		00.0				
SIGNATURE		(if appropriate	REGISTRATION NO. 45,104 (if appropriate)			
TYPED or PRINTED NAME Gina N. Shishima Docket N			per: ARCD:405USP1			
TELEPHONE 512-536-3081						

to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mall Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO

PROVISIONAL APPLICATION COVER SHEET

Additional Page

PTO/SB/16 (02-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ARCD:405USP1 **Docket Number** INVENTOR(S)/APPLICANT(S) Residence Given Name (first and middle [if any]) Family or Surname (City and either State or Foreign Country) Innocenti Chicago, IL Federico Kroetz San Francisco, CA Deanna L. Undevia Chicago, IL Samir

Number	2	of	2
LAGINDEL	-	0,	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.